ATE531812T1 - Humanisierung von nager-antikörpern - Google Patents

Humanisierung von nager-antikörpern

Info

Publication number
ATE531812T1
ATE531812T1 AT98960758T AT98960758T ATE531812T1 AT E531812 T1 ATE531812 T1 AT E531812T1 AT 98960758 T AT98960758 T AT 98960758T AT 98960758 T AT98960758 T AT 98960758T AT E531812 T1 ATE531812 T1 AT E531812T1
Authority
AT
Austria
Prior art keywords
antibody
humanization
rodent antibodies
complementarity determining
determining region
Prior art date
Application number
AT98960758T
Other languages
English (en)
Inventor
Carlos Barbas
Christoph Rader
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25532007&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE531812(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of ATE531812T1 publication Critical patent/ATE531812T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT98960758T 1997-12-05 1998-12-04 Humanisierung von nager-antikörpern ATE531812T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98601697A 1997-12-05 1997-12-05
PCT/US1998/025828 WO1999029888A1 (en) 1997-12-05 1998-12-04 Humanization of murine antibody

Publications (1)

Publication Number Publication Date
ATE531812T1 true ATE531812T1 (de) 2011-11-15

Family

ID=25532007

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98960758T ATE531812T1 (de) 1997-12-05 1998-12-04 Humanisierung von nager-antikörpern

Country Status (13)

Country Link
US (1) US7087409B2 (de)
EP (1) EP1034298B1 (de)
JP (1) JP4460155B2 (de)
AT (1) ATE531812T1 (de)
AU (1) AU760562B2 (de)
BR (1) BR9813365A (de)
CA (1) CA2312208C (de)
CY (1) CY1112365T1 (de)
DK (1) DK1034298T3 (de)
ES (1) ES2375931T3 (de)
IL (2) IL136544A0 (de)
PT (1) PT1034298E (de)
WO (1) WO1999029888A1 (de)

Families Citing this family (1054)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
ES2277460T3 (es) 1998-12-14 2007-07-01 Genetics Institute, Llc Cadena del receptor de la citoquina.
EP1436329A4 (de) * 2001-09-20 2005-04-27 Alexion Pharma Inc Anti-pdgf-antikörper und verfahren zur herstellung konstruierter antikörper
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
EP1660186B1 (de) * 2003-08-18 2013-12-25 MedImmune, LLC Humanisierung von antikörpern
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
EP2990053A1 (de) 2004-01-20 2016-03-02 KaloBios Pharmaceuticals, Inc. Antikörper-spezifitätstransfer mit minimal essenziell bindenden determinanten
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
PL2343380T3 (pl) 2004-11-16 2020-03-31 Humanigen, Inc. Wymiana kasety dla regionu zmiennego immunoglobuliny
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
CN101687031B (zh) 2006-10-27 2014-05-14 勒帕斯公司 用于治疗眼疾和眼病的组合物及方法
KR101581279B1 (ko) 2006-10-27 2015-12-31 엘파스, 인크. 스핑고신-1-포스페이트 결합을 위한 조성물 및 방법
CA2677771A1 (en) 2007-03-01 2008-09-04 Symphogen A/S Method for cloning cognate antibodies
BRPI0808418A2 (pt) 2007-03-02 2014-07-22 Genentech, Inc Predição de resposta a um inibidor de her
JP2010527916A (ja) * 2007-04-23 2010-08-19 ワイス・エルエルシー Ｉｌ−１３関連障害を治療する方法および組成物ならびにその治療をモニターする方法
US20110064744A1 (en) * 2007-05-30 2011-03-17 Sabbadini Roger A Prevention and treatment of pain using antibodies to lysophosphatidic acid
WO2008150841A1 (en) 2007-05-30 2008-12-11 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
CA3128656A1 (en) 2007-08-22 2009-02-26 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
DK3059246T3 (en) 2007-09-26 2018-10-01 Chugai Pharmaceutical Co Ltd Modified constant region of an antibody
US20090087443A1 (en) * 2007-09-27 2009-04-02 Bartels Stephen P Pharmacological Adjunctive Treatment Associated with Glaucoma Filtration Surgery
US8361465B2 (en) * 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
CN101854946B (zh) 2007-11-08 2013-07-03 尼尔詹尼克斯肿瘤研究公司 结肠癌和胰腺癌的重组单克隆抗体和相应抗原
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
NZ592054A (en) 2008-10-13 2013-06-28 Inst Research In Biomedicine Dengue virus neutralizing antibodies and uses thereof
EP3524620A1 (de) 2008-10-14 2019-08-14 Genentech, Inc. Immunglobulinvarianten und ihre verwendung
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
AR074369A1 (es) * 2008-11-20 2011-01-12 Genentech Inc Anticuerpos anti-unc 5b (receptor de netrina) y metodos de uso
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
JP2012511026A (ja) * 2008-12-05 2012-05-17 エルパス・インコーポレイテッド 抗脂抗体結晶構造を用いた抗体設計
US8401799B2 (en) * 2008-12-05 2013-03-19 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
HUE065752T2 (hu) 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
BRPI0918204A2 (pt) 2008-12-23 2015-12-08 Genentech Inc igv variante composição farmaceutica e kit
EP3543256A1 (de) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modifizierte antikörperzusammensetzungen, verfahren zur herstellung und verwendung davon
BRPI1011384A2 (pt) 2009-02-23 2016-03-15 Cytomx Therapeutics Inc pro-proteinas e seus metodos de uso
WO2010098863A1 (en) * 2009-02-26 2010-09-02 Lpath, Inc. Humanized platelet activating factor antibody design using anti-lipid antibody templates
AU2010229479B2 (en) 2009-03-25 2013-03-28 Genentech, Inc. Novel anti-alpha5beta1 antibodies and uses thereof
US20100297127A1 (en) 2009-04-08 2010-11-25 Ghilardi Nico P Use of il-27 antagonists to treat lupus
WO2010121093A2 (en) * 2009-04-17 2010-10-21 Lpath, Inc. Humanized antibody compositions and methods for binding lysophosphatidic acid
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
WO2011006001A1 (en) 2009-07-09 2011-01-13 Genentech, Inc. Animal model for the evaluation of adjuvant therapies of cancer
BR112012000735A2 (pt) 2009-07-13 2016-11-16 Genentech Inc "métodos, kits e conjuntos de compostos"
AR077595A1 (es) 2009-07-27 2011-09-07 Genentech Inc Tratamientos de combinacion
WO2011014750A1 (en) 2009-07-31 2011-02-03 Genentech, Inc. Inhibition of tumor metastasis using bv8- or g-csf-antagonists
BR112012002974B1 (pt) 2009-08-11 2022-06-07 Genentech, Inc Processo para produzir um anticorpo em uma célula hospedeira de célula ovário de hamster chinês (cho) expressando o referido polipeptídeo
EP2464744A1 (de) 2009-08-14 2012-06-20 F. Hoffmann-La Roche AG Biologische marker zur überwachung der patientenreaktion auf vegf-antagonisten
EP2473522B1 (de) 2009-09-02 2016-08-17 Genentech, Inc. Smoothened-mutant und verfahren zu seiner anwendung
CN102597776A (zh) 2009-09-11 2012-07-18 霍夫曼-拉罗奇有限公司 鉴定响应抗癌剂的可能性升高的患者的方法
JP5606537B2 (ja) 2009-09-17 2014-10-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 癌患者における診断使用のための方法及び組成物
CA2775880A1 (en) 2009-09-30 2011-04-07 Genentech, Inc. Anti-notch3 antagonist antibodies to treat gamma secretase inhibitor responsive and anti-notch1 antagonist antibody unresponsive t-cell leukemias
WO2011060015A1 (en) 2009-11-11 2011-05-19 Genentech, Inc. Methods and compositions for detecting target proteins
EP2509626B1 (de) 2009-12-11 2016-02-10 F.Hoffmann-La Roche Ag Anti-vegf-c-antikörper und verfahren zu ihrer verwendung
SG181834A1 (en) 2009-12-21 2012-07-30 Genentech Inc Antibody formulation
JP5852010B2 (ja) 2009-12-23 2016-02-03 ジェネンテック， インコーポレイテッド 抗Ｂｖ８抗体およびその使用
WO2011092593A2 (en) 2010-01-20 2011-08-04 Institute For Research In Biomedicine Hiv-1 neutralizing antibodies and uses thereof
MX2012008958A (es) 2010-02-18 2012-08-23 Genentech Inc Antagonista de neurogulina y usos de los mismos para el tratamiento contra el cancer.
WO2011106723A2 (en) * 2010-02-26 2011-09-01 Lpath, Inc. Anti-paf antibodies
MX2012010853A (es) 2010-03-24 2013-01-29 Genentech Inc Anticuerpos anti-lrp6.
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2011153224A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
WO2011159980A1 (en) 2010-06-18 2011-12-22 Genentech, Inc. Anti-axl antibodies and methods of use
WO2011161189A1 (en) 2010-06-24 2011-12-29 F. Hoffmann-La Roche Ag Anti-hepsin antibodies and methods of use
JP2013539962A (ja) 2010-07-09 2013-10-31 ジェネンテック， インコーポレイテッド 抗ニューロピリン抗体及び使用方法
BR112013001433A2 (pt) 2010-07-19 2016-05-31 Hoffmann La Roche método de identificação de pacientes com maior probabilidade de responder a terapia anticâncer
CN103109189A (zh) 2010-07-19 2013-05-15 霍夫曼-拉罗奇有限公司 鉴定响应抗癌疗法的可能性升高的患者的方法
WO2012010582A1 (en) 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
JP2013541501A (ja) 2010-08-03 2013-11-14 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 慢性リンパ性白血病（ｃｌｌ）のバイオマーカー
BR112013002532A2 (pt) 2010-08-05 2016-05-31 Hoffmann La Roche proteína de fusão de citocina anti-viral do anticorpo anti-mhc
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
CN104474546A (zh) 2010-08-13 2015-04-01 弗·哈夫曼-拉罗切有限公司 用于疾病治疗的针对IL-1β和IL-18的抗体
SG187746A1 (en) 2010-08-13 2013-03-28 Roche Glycart Ag Anti-fap antibodies and methods of use
KR101653030B1 (ko) 2010-08-13 2016-08-31 로슈 글리카트 아게 항-테나신-c a２ 항체 및 이의 사용 방법
CA2809369A1 (en) 2010-08-27 2012-03-01 Stem Centrx, Inc. Notum protein modulators and methods of use
CA2808236A1 (en) 2010-08-31 2012-03-08 Genentech, Inc. Biomarkers and methods of treatment
BR112013005116A2 (pt) 2010-09-03 2019-09-24 Stem Centrx Inc moduladores e métodos de uso
EP2625197B1 (de) 2010-10-05 2016-06-29 Genentech, Inc. Smoothened-mutant und verfahren zu seiner anwendung
AR083819A1 (es) 2010-11-10 2013-03-27 Genentech Inc UN ANTICUERPO QUE SE UNE A BACE1 (ENZIMA 1 DE DISOCIACION DE PROTEINA PRECURSORA DEL AMILOIDE DE SITIO b), METODOS Y COMPOSICIONES PARA INMUNOTERAPIA PARA ENFERMEDAD NEURAL
MX356400B (es) 2010-12-08 2018-05-28 Abbvie Stemcentrx Llc Moduladores novedosos y metodos de uso.
JP6005657B2 (ja) 2010-12-16 2016-10-12 ジェネンテック， インコーポレイテッド Ｔｈ２阻害に関連する診断及び治療
WO2012087962A2 (en) 2010-12-20 2012-06-28 Genentech, Inc. Anti-mesothelin antibodies and immunoconjugates
CA2820953A1 (en) 2010-12-22 2012-06-28 Genentech, Inc. Anti-pcsk9 antibodies and methods of use
CN103282054A (zh) 2011-01-03 2013-09-04 弗·哈夫曼-拉罗切有限公司 抗dig抗体和与肽缀合的地高辛配基的复合物的药物组合物
EP2672999A2 (de) 2011-02-10 2013-12-18 Roche Glycart AG Verbesserte immuntherapie
US9266938B2 (en) 2011-02-10 2016-02-23 Roche Glycart Ag Mutant interleukin-2 polypeptides
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
EP3556774B1 (de) 2011-03-11 2024-01-03 Beth Israel Deaconess Medical Center Inc. Anti-cd40-antikörper und verwendungen davon
BR112013024574B1 (pt) 2011-03-29 2022-08-09 Roche Glycart Ag Anticorpo e uso do anticorpo
MX342240B (es) 2011-04-07 2016-09-21 Genentech Inc Anticuerpos anti-fgfr4 y metodos de uso.
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
MX2013013054A (es) 2011-05-12 2014-02-20 Genentech Inc Metodo de monitoreo de lc-ms/ms de reaccion multiple para detectar anticuerpos terapeuticos en muestras de animales utilizando peptidos de firma de estructura.
PE20140995A1 (es) 2011-05-16 2014-08-23 Genentech Inc Agonistas de fgfr1 y sus metodos de uso
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
KR101629073B1 (ko) 2011-06-15 2016-06-09 에프. 호프만-라 로슈 아게 항-인간 에리스로포이에틴 수용체 항체 및 이의 사용 방법
BR112013030472A2 (pt) 2011-06-30 2019-09-24 Genentech Inc formulação farmacêutica, artigo de fabricação e método
JP2013040160A (ja) 2011-07-01 2013-02-28 Genentech Inc 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用
EA026924B1 (ru) 2011-08-01 2017-05-31 Дженентек, Инк. Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek
KR20140057326A (ko) 2011-08-17 2014-05-12 제넨테크, 인크. 뉴레귤린 항체 및 그의 용도
WO2013025944A1 (en) 2011-08-17 2013-02-21 Genentech, Inc. Inhibition of angiogenesis in refractory tumors
AR087601A1 (es) 2011-08-23 2014-04-03 Roche Glycart Ag Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de utilizacion
CN107586340B (zh) 2011-08-23 2022-01-21 罗切格利卡特公司 对t细胞活化性抗原和肿瘤抗原特异性的双特异性抗体及使用方法
WO2013026832A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Anti-mcsp antibodies
WO2013026837A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
HRP20181355T1 (hr) 2011-08-23 2018-10-19 Roche Glycart Ag Bispecifične molekule koje se vežu na antigen
PH12013502531A1 (en) 2011-08-23 2014-01-20 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
BR112014005720A2 (pt) 2011-09-15 2017-12-12 Genentech Inc método de seleção e/ou identificação de um antagonista de usp1, antagonista de uaf1 e/ou um antagonista de id que promove uma alteração no destino celular do dito método
US20130078252A1 (en) 2011-09-19 2013-03-28 Genentech, Inc. Combination treatments comprising c-met antagonists and b-raf antagonists
US9663573B2 (en) 2011-10-05 2017-05-30 Genentech, Inc. Methods of treating liver conditions using Notch2 antagonists
JP6532678B2 (ja) 2011-10-14 2019-06-19 ジェネンテック， インコーポレイテッド 抗ＨｔｒＡ１抗体及び使用方法
MX2014004426A (es) 2011-10-15 2014-07-09 Genentech Inc Metodos de uso de antagonistas de scd1.
WO2013059531A1 (en) 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
CA2850034A1 (en) 2011-10-28 2013-05-02 Genentech, Inc. Therapeutic combinations and methods of treating melanoma
TW201326193A (zh) 2011-11-21 2013-07-01 Genentech Inc 抗－ｃ－ｍｅｔ抗體之純化
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
US20140335084A1 (en) 2011-12-06 2014-11-13 Hoffmann-La Roche Inc. Antibody formulation
HK1200849A1 (en) 2011-12-22 2015-08-14 F. Hoffmann-La Roche Ag Full length antibody display system for eukaryotic cells and its use
CN104114701A (zh) 2011-12-22 2014-10-22 弗·哈夫曼-拉罗切有限公司 表达载体组织、新的生产用细胞产生方法及其在重组产生多肽中的用途
CN113896787A (zh) 2011-12-22 2022-01-07 弗·哈夫曼-拉罗切有限公司 表达载体元件组合、新的生产用细胞产生方法及其在重组产生多肽中的用途
WO2013096791A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Process for making high concentration protein formulations
EP2793947B1 (de) 2011-12-23 2021-02-03 Innate Pharma Enzymatische konjugation von polypeptiden
US10774132B2 (en) 2012-01-09 2020-09-15 The Scripps Research Instittue Ultralong complementarity determining regions and uses thereof
WO2013106489A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
BR112014017320A2 (en) 2012-01-13 2018-05-29 Genentech, Inc method for determining whether a patient is prone to respond to treatment with a vegf antagonist, method for optimizing the therapeutic efficacy of a vegf antagonist, method for selecting a therapy, method for identifying a biomarker, and method for diagnosing an angiogenic disorder
JP2015506944A (ja) 2012-01-18 2015-03-05 ジェネンテック， インコーポレイテッド Ｆｇｆ１９修飾薬を使用する方法
CA2862422A1 (en) 2012-01-18 2013-07-25 Genentech, Inc. Anti-lrp5 antibodies and methods of use
AR091305A1 (es) 2012-01-31 2015-01-28 Genentech Inc ANTICUERPOS ANTI-IgE Y SUS METODOS DE USO
MX366804B (es) 2012-02-11 2019-07-25 Genentech Inc Translocaciones de la r-espondina y sus metodos de uso.
SI2814587T1 (en) 2012-02-15 2018-08-31 F. Hoffmann-La Roche Ag Affinity chromatography based on the Fc receptor
EP3093294A1 (de) 2012-02-24 2016-11-16 Stemcentrx, Inc. Dll3-antikörper und verfahren zur verwendung
KR102099073B1 (ko) 2012-02-24 2020-04-10 애브비 스템센트알엑스 엘엘씨 항 ｓｅｚ6 항체들 및 사용 방법
BR112014018964A2 (pt) 2012-03-13 2020-05-12 F. Hoffmann-La Roche Ag Anticorpo anti-vegf e uso de um anticorpo anti-vegf
WO2013148315A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
MX2014011582A (es) 2012-03-30 2014-11-21 Genentech Inc Metodos y composiciones de diagnostico para el tratamiento de cancer.
WO2013158485A1 (en) 2012-04-18 2013-10-24 Massachusetts Institute Of Technology Menainv and cancer invasion and metastasis
JP6242865B2 (ja) 2012-05-01 2017-12-06 ジェネンテック， インコーポレイテッド 抗ｐｍｅｌ１７抗体および免疫複合体
US9480449B2 (en) 2012-05-03 2016-11-01 Fibrogen, Inc. Methods for treating idiopathic pulmonary fibrosis
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
WO2013177470A1 (en) 2012-05-23 2013-11-28 Genentech, Inc. Selection method for therapeutic agents
RU2689760C2 (ru) 2012-05-31 2019-05-30 Дженентек, Инк. Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов
JP2015530867A (ja) 2012-06-15 2015-10-29 ジェネンテック， インコーポレイテッド 抗ｐｃｓｋ９抗体、製剤、投薬、及び使用方法
RU2630296C2 (ru) 2012-07-04 2017-09-06 Ф. Хоффманн-Ля Рош Аг Антитела к биотину и способы их применения
CA2872184A1 (en) 2012-07-04 2014-01-09 F. Hoffmann-La Roche Ag Anti-theophylline antibodies and methods of use
SI2869848T1 (sl) 2012-07-04 2017-01-31 F. Hoffmann-La Roche Ag Kovalentno vezani konjugati antigen-protitelo
SI2870247T1 (sl) 2012-07-05 2019-10-30 Hoffmann La Roche Ekspresijski in sekrecijski sistem
IN2014DN10652A (de) 2012-07-09 2015-09-11 Genentech Inc
WO2014011521A1 (en) 2012-07-09 2014-01-16 Genentech, Inc. Immunoconjugates comprising anti - cd79b antibodies
SG11201500142RA (en) 2012-07-09 2015-02-27 Genentech Inc Immunoconjugates comprising anti-cd22 antibodies
TW201406785A (zh) 2012-07-09 2014-02-16 Genentech Inc 抗ｃｄ２２抗體及免疫結合物
US10132799B2 (en) 2012-07-13 2018-11-20 Innate Pharma Screening of conjugated antibodies
EP2872534B1 (de) 2012-07-13 2018-08-08 Roche Glycart AG Bispezifische anti-vegf-/anti-ang-2-antikörper und ihre verwendung bei der behandlung von vaskulären augenerkrankungen
CN104662045B (zh) 2012-08-07 2019-04-05 罗切格利卡特公司 包含两种工程化改造成具有降低的和升高的效应器功能的抗体的组合物改进的免疫疗法
SG11201500903XA (en) 2012-08-07 2015-03-30 Genentech Inc Combination therapy for the treatment of glioblastoma
PE20150645A1 (es) 2012-08-08 2015-05-11 Roche Glycart Ag Proteinas de fusion de interleuquina 10 y usos de las mismas
CA2878626A1 (en) 2012-08-09 2014-02-13 Roche Glycart Ag Asgpr antibodies and uses thereof
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
IN2015DN00140A (de) * 2012-08-31 2015-06-12 Argen X Bv
BR112015007120A2 (pt) 2012-10-08 2017-12-12 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo
HK1214831A1 (zh) 2012-11-05 2016-08-05 Foundation Medicine, Inc. 新型融合分子及其应用
AU2013337277B2 (en) 2012-11-05 2018-03-08 Foundation Medicine, Inc. Novel NTRK1 fusion molecules and uses thereof
EP2917243B1 (de) 2012-11-08 2018-03-14 F.Hoffmann-La Roche Ag Die beta-haarnadel von her3 bindende her3-antikörper
US10036010B2 (en) 2012-11-09 2018-07-31 Innate Pharma Recognition tags for TGase-mediated conjugation
AU2013345072B2 (en) 2012-11-13 2017-12-07 Genentech, Inc. Anti-hemagglutinin antibodies and methods of use
WO2014107739A1 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
US10980804B2 (en) 2013-01-18 2021-04-20 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
RU2019109456A (ru) 2013-02-22 2019-04-10 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Новые конъюгаты антител и их применения
EP2958592A1 (de) 2013-02-22 2015-12-30 F. Hoffmann-La Roche AG Verfahren zur behandlung von krebs und zur verhinderung von arzneimittelresistenz
WO2014130923A2 (en) 2013-02-25 2014-08-28 Genentech, Inc. Methods and compositions for detecting and treating drug resistant akt mutant
WO2014131711A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
UA119320C2 (uk) 2013-02-26 2019-06-10 Рош Глікарт Аг Активуюча т-клітини біспецифічна антигензв'язувальна молекула
KR20150123811A (ko) 2013-02-26 2015-11-04 로슈 글리카트 아게 항-mcsp 항체
CN110845618A (zh) 2013-02-26 2020-02-28 罗切格利卡特公司 双特异性t细胞活化抗原结合分子
RU2015137610A (ru) 2013-03-06 2017-04-10 Дженентек, Инк. Способы лечения и профилактики лекарственной резистентности злокачественных опухолей
AR095398A1 (es) 2013-03-13 2015-10-14 Genentech Inc Formulaciones con oxidación reducida
AR095399A1 (es) 2013-03-13 2015-10-14 Genentech Inc Formulaciones con oxidación reducida, método
MY199135A (en) 2013-03-13 2023-10-17 Genentech Inc Formulations with reduced oxidation
CN105209069B (zh) 2013-03-13 2019-08-23 豪夫迈·罗氏有限公司 抗体配制剂
CA2904169C (en) 2013-03-13 2021-12-07 Genentech, Inc. Formulations with reduced oxidation
BR112015022576A2 (pt) 2013-03-14 2017-10-24 Genentech Inc produto farmacêutico e seu uso, kit e método para tratar uma disfunção hiperproliferativa
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
HK1220916A1 (zh) 2013-03-14 2017-05-19 基因泰克公司 治疗癌症和预防癌症药物抗性的方法
US10351626B2 (en) 2013-03-14 2019-07-16 The Scripps Research Institute Targeting agent antibody conjugates and uses thereof
EA201591750A1 (ru) 2013-03-14 2016-05-31 Дженентек, Инк. Антитела против b7-h4 и иммуноконъюгаты
US9649375B2 (en) 2013-03-14 2017-05-16 The Administrators Of The Tulane Educational Fund Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith
US9598485B2 (en) 2013-03-15 2017-03-21 Ac Immune S.A. Anti-tau antibodies and methods of use
CN105339001A (zh) 2013-03-15 2016-02-17 基因泰克公司 治疗癌症和预防癌症耐药性的方法
KR20250091304A (ko) 2013-03-15 2025-06-20 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
US20140328849A1 (en) 2013-03-15 2014-11-06 Genentech, Inc. Anti-crth2 antibodies and methods of use
US9550829B2 (en) 2013-03-15 2017-01-24 Genentech, Inc. Compositions and methods for diagnosis and treatment of hepatic cancers
EP2968582B1 (de) 2013-03-15 2020-07-01 Innate Pharma Festphasen-tgase-vermittelte konjugation von antikörpern
HK1213179A1 (zh) 2013-03-15 2016-06-30 豪夫迈‧罗氏有限公司 细胞培养培养基和抗体生产方法
KR20240122922A (ko) 2013-03-27 2024-08-13 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
WO2014169076A1 (en) 2013-04-09 2014-10-16 Annexon,,Inc. Methods of treatment for neuromyelitis optica
EP3628685A1 (de) 2013-04-29 2020-04-01 F. Hoffmann-La Roche AG Menschliche fcrn-bindungsmodifizierte antikörper und verfahren zur verwendung
US20160068613A1 (en) 2013-04-29 2016-03-10 Hoffmann-La Roche Inc. Fc-receptor binding modified asymmetric antibodies and methods of use
SG10201810481UA (en) 2013-04-29 2018-12-28 Hoffmann La Roche Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
SG11201509566RA (en) 2013-05-20 2015-12-30 Genentech Inc Anti-transferrin receptor antibodies and methods of use
EP3010547B1 (de) 2013-06-20 2021-04-21 Innate Pharma Enzymatische konjugation von polypeptiden
CN105517577A (zh) 2013-06-21 2016-04-20 先天制药公司 多肽的酶促偶联
BR112016000106B1 (pt) 2013-07-09 2023-11-21 Annexon, Inc. Anticorpos anti-c1q e usos dos mesmos, célula de hibridoma, composição farmacêutica e métodos de detecção de sinapses em uma amostra biológica referências cruzadas a pedidos relacionados
AU2014290069B2 (en) 2013-07-16 2019-01-03 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
EP3022224A2 (de) 2013-07-18 2016-05-25 Fabrus, Inc. Antikörper mit ultralangen komplementaritätsbestimmenden regionen
JP6687520B2 (ja) 2013-07-18 2020-04-22 トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー 極めて長い相補性決定領域を有するヒト化抗体
EP4105236A1 (de) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antikörper zur behandlung von entzündlichen darmerkrankungen
PH12019501393B1 (en) 2013-08-01 2022-09-07 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
WO2015031698A1 (en) 2013-08-28 2015-03-05 Stem Centrx, Inc. Site-specific antibody conjugation methods and compositions
JP2016538318A (ja) 2013-08-28 2016-12-08 ステムセントリックス， インコーポレイテッド 新規ｓｅｚ６モジュレーターおよび使用方法
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
SG11201601770YA (en) * 2013-09-12 2016-04-28 Halozyme Inc Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
AR097685A1 (es) 2013-09-17 2016-04-06 Genentech Inc Métodos de uso de anticuerpos anti-lgr5
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
SI3049441T1 (sl) 2013-09-27 2020-03-31 F. Hoffmann-La Roche Ag Formulacije protiteles proti PD-L1
JP2016537965A (ja) 2013-10-11 2016-12-08 ジェネンテック， インコーポレイテッド Ｎｓｐ４阻害剤及び使用方法
CN105744954B (zh) 2013-10-18 2021-03-05 豪夫迈·罗氏有限公司 抗rspo2和/或抗rspo3抗体及其用途
BR112016008694A2 (pt) 2013-10-23 2017-10-03 Genentech Inc Métodos de previsão da reação de pacientes com asma, de previsão da capacidade de reação de pacientes com asma, de identificação de pacientes com asma, de tratamento de pacientes portadores de asma e de tratamento de asma, uso de um kit e kit
PE20160870A1 (es) 2013-11-06 2016-09-09 Abbvie Stemcentrx Llc Anticuerpos anti-claudina novedosos y metodos de uso
MX374290B (es) * 2013-11-07 2025-03-06 Ono Pharmaceutical Co Combinación de un anticuerpo anti cd20 con un inhibidor de btk para usarse en el tratamiento de cáncer.
WO2015075011A1 (en) 2013-11-21 2015-05-28 F. Hoffmann-La Roche Ag ANTI-alpha-SYNUCLEIN ANTIBODIES AND METHODS OF USE
SG11201604632PA (en) 2013-12-09 2016-07-28 Allakos Inc Anti-siglec-8 antibodies and methods of use thereof
MX2016007576A (es) 2013-12-13 2016-10-03 Genentech Inc Anticuerpos e inmunoconjugados anti-cd33.
MX2016007885A (es) 2013-12-17 2017-01-11 Genentech Inc Metodos de tratamiento de cancer usando antagonistas de union del eje de pd-1 y un anticuerpo anti-cd20.
KR102225489B1 (ko) 2013-12-17 2021-03-10 제넨테크, 인크. 항-cd3 항체 및 이의 사용 방법
NZ760065A (en) 2013-12-17 2022-12-23 Genentech Inc Methods of treating cancers using pd-1 axis binding antagonists and taxanes
CA2934028A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
AU2014368696A1 (en) 2013-12-20 2016-06-02 F. Hoffmann-La Roche Ag Humanized anti-Tau(pS422) antibodies and methods of use
TWI728373B (zh) 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
MX373017B (es) 2014-01-03 2020-04-28 Hoffmann La Roche Conjugados de toxina polipeptidica-anticuerpo unidos covalentemente.
ES2895752T3 (es) 2014-01-03 2022-02-22 Hoffmann La Roche Anticuerpos biespecíficos anti-hapteno/anti-receptor de la barrera hematoencefálica, complejos de los mismos y su uso como lanzaderas a través de la barrera hematoencefálica
MX373856B (es) 2014-01-03 2020-03-25 Hoffmann La Roche Conjugados helicoidales-anticuerpo anti-helicoidal unidos covalentemente y usos de los mismos.
CA2932547C (en) 2014-01-06 2023-05-23 F. Hoffmann-La Roche Ag Monovalent blood brain barrier shuttle modules
WO2015107026A1 (en) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn- and maintained protein a-binding properties
KR20160111469A (ko) 2014-01-24 2016-09-26 제넨테크, 인크. 항-steap1 항체 및 면역접합체를 사용하는 방법
CA2937539A1 (en) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened and methods of using the same
CN111423513A (zh) 2014-02-06 2020-07-17 豪夫迈·罗氏有限公司 白介素-2融合蛋白和其用途
AU2015214058B2 (en) 2014-02-08 2020-07-09 Genentech, Inc. Methods of treating Alzheimer's Disease
TWI769970B (zh) 2014-02-08 2022-07-11 美商建南德克公司 治療阿茲海默症之方法
WO2015123325A1 (en) 2014-02-12 2015-08-20 Genentech, Inc. Anti-jagged1 antibodies and methods of use
KR20170008202A (ko) 2014-02-21 2017-01-23 애브비 스템센트알엑스 엘엘씨 흑색종에 사용하기 위한 항-ｄｌｌ3 항체 및 약물 접합체
CN106029693A (zh) 2014-02-21 2016-10-12 豪夫迈·罗氏有限公司 抗il-13/il-17双特异性抗体及其用途
JP6825909B2 (ja) 2014-02-28 2021-02-03 アラコス インコーポレイテッド シグレック−８関連疾患を処置するための方法および組成物
BR112016020822A2 (pt) 2014-03-14 2017-10-03 Genentech Inc Métodos e composições para secreção de polipeptídeos heterólogos
WO2015140591A1 (en) 2014-03-21 2015-09-24 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
BR112016023417A2 (pt) 2014-03-21 2019-04-16 F. Hoffmann-La Roche Ag predição in vitro de meia-vida in vivo
BR112016021383A2 (pt) 2014-03-24 2017-10-03 Genentech Inc Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
RU2016142476A (ru) 2014-03-31 2018-05-07 Дженентек, Инк. Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
HRP20192285T1 (hr) 2014-03-31 2020-03-06 F. Hoffmann - La Roche Ag Anti-ox40 protutijela i postupci uporabe
KR102376287B1 (ko) 2014-04-02 2022-03-17 에프. 호프만-라 로슈 아게 다중특이적 항체 경쇄 잘못짝짓기의 검출 방법
MX388380B (es) 2014-04-18 2025-03-19 Acceleron Pharma Inc Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes.
WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
RU2016150370A (ru) 2014-05-22 2018-06-26 Дженентек, Инк. Антитела и иммуноконъюгаты против GPC3
MX2016015163A (es) 2014-05-23 2017-03-03 Genentech Inc Biomarcadores mit y metodos para su uso.
KR20170010785A (ko) 2014-06-11 2017-02-01 제넨테크, 인크. 항-lgr5 항체 및 이의 용도
CN107073121A (zh) 2014-06-13 2017-08-18 基因泰克公司 治疗及预防癌症药物抗性的方法
TN2016000553A1 (en) 2014-06-13 2018-04-04 Acceleron Pharma Inc Methods and compositions for treating ulcers
PT3157951T (pt) * 2014-06-17 2020-08-24 Academia Sinica Anticorpos anti-ige humanizados que reticulam cd23 em linfócitos b, mas não sensibilizam mastócitos
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
EP3164419B1 (de) 2014-06-26 2024-07-24 F. Hoffmann-La Roche AG Anti-brdu-antikörper und verfahren zur verwendung
SI3164492T1 (sl) 2014-07-03 2020-02-28 F. Hoffmann-La Roche Ag Sistem polipeptidne ekspresije
BR112017000130A2 (pt) 2014-07-11 2018-01-09 Genentech Inc método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer
BR112017000497B1 (pt) 2014-07-11 2023-12-26 Ventana Medical Systems, Inc Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1
WO2016011052A1 (en) 2014-07-14 2016-01-21 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
EP3563870A1 (de) 2014-07-15 2019-11-06 F. Hoffmann-La Roche AG Verfahren zur behandlung von krebs unter verwendung von pd-1-achsen-bindenden antagonisten und mek-inhibitoren
SMT202400235T1 (it) 2014-08-04 2024-07-09 Hoffmann La Roche Molecole bispecifiche leganti l’antigene di attivazione delle cellule t
EA201790342A1 (ru) 2014-08-08 2017-07-31 ЭЛЕКТОР ЭлЭлСи Антитела к trem2 и способы их применения
ES3034398T3 (en) 2014-08-28 2025-08-18 Bioatla Inc Conditionally active chimeric antigen receptors for modified t-cells
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
US10059768B2 (en) 2014-09-12 2018-08-28 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
AU2015314954B2 (en) 2014-09-12 2021-05-13 Genentech, Inc. Anti-HER2 antibodies and immunoconjugates
SG11201701627PA (en) 2014-09-12 2017-03-30 Genentech Inc Anti-cll-1 antibodies and immunoconjugates
JP7072384B2 (ja) 2014-09-15 2022-05-20 ジェネンテック， インコーポレイテッド 抗体製剤
JP6897952B2 (ja) * 2014-09-16 2021-07-07 国立大学法人東京海洋大学 濃縮された生着能をもつ未分化生殖細胞を用いた生殖細胞系列への分化誘導方法
WO2016044396A1 (en) 2014-09-17 2016-03-24 Genentech, Inc. Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
DK3262071T3 (da) 2014-09-23 2020-06-15 Hoffmann La Roche Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
JP2017536102A (ja) 2014-10-16 2017-12-07 ジェネンテック， インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法
US10626176B2 (en) 2014-10-31 2020-04-21 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind B7-H4
AU2015343337A1 (en) 2014-11-03 2017-06-15 Genentech, Inc. Assays for detecting T cell immune subsets and methods of use thereof
CN107109484B (zh) 2014-11-03 2021-12-14 豪夫迈·罗氏有限公司 用于ox40激动剂治疗的功效预测和评估的方法和生物标志物
WO2016073685A1 (en) 2014-11-05 2016-05-12 Annexon, Inc. Humanized anti-complement factor c1q antibodies and uses thereof
CA2966558C (en) 2014-11-05 2024-03-12 Genentech, Inc. Methods of producing two chain proteins in bacteria
AU2015342964B2 (en) 2014-11-05 2021-06-24 Genentech, Inc. Methods of producing two chain proteins in bacteria
EP3215524B1 (de) 2014-11-06 2021-01-13 F.Hoffmann-La Roche Ag Fc-region-varianten mit modifizierten eigenschaften der fcrn- und protein a-bindung
WO2016073157A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
KR20170072343A (ko) 2014-11-06 2017-06-26 제넨테크, 인크. Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법
SI3215528T1 (sl) 2014-11-06 2019-11-29 Hoffmann La Roche Variante regije Fc s spremenjeno vezavo FcRn in postopki uporabe
CA2960297A1 (en) 2014-11-10 2016-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
EP3217787B1 (de) 2014-11-10 2019-04-17 F.Hoffmann-La Roche Ag Tiermodell für nephropathie und mittel zur behandlung davon
DK3489256T3 (da) 2014-11-14 2021-05-25 Hoffmann La Roche Antigenbindende molekyler omfattende en TNF-familieligandtrimer
MX2017006320A (es) 2014-11-17 2017-08-10 Genentech Inc Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
JP6993228B2 (ja) 2014-11-19 2022-03-03 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
EP3221364B1 (de) 2014-11-19 2020-12-16 Genentech, Inc. Antikörper gegen bace1 und deren verwendung zur immuntherapie von nervenerkrankungen
WO2016081643A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
BR112017010513A2 (pt) 2014-11-20 2018-04-03 F. Hoffmann-La Roche Ag ?cadeias leves comuns e métodos de uso?
US10517898B2 (en) 2014-11-20 2019-12-31 The Regents Of The University Of California Compositions and methods related to hematologic recovery
RU2753902C2 (ru) 2014-11-20 2021-08-24 Ф.Хоффманн-Ля Рош Аг Комбинированная терапия на основе активирующих т-клетки биспецифических антигенсвязывающих молекул против cd3 и фолатного рецептора 1 (folr1) и антагонистов, связывающихся с осью pd-1
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
CN107206088A (zh) 2014-12-05 2017-09-26 豪夫迈·罗氏有限公司 使用pd‑1轴拮抗剂和hpk1拮抗剂用于治疗癌症的方法和组合物
AU2015358325A1 (en) 2014-12-05 2017-05-25 Genentech, Inc. Anti-CD79b antibodies and methods of use
WO2016094566A2 (en) 2014-12-10 2016-06-16 Genentech, Inc. Blood brain barrier receptor antibodies and methods of use
EP3234598B1 (de) 2014-12-18 2019-11-06 F.Hoffmann-La Roche Ag Assay und verfahren zur bestimmung cdc-entlockender antikörper
TWI656133B (zh) 2014-12-19 2019-04-11 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Ｆｃ區域之多胜肽及使用方法
KR101838645B1 (ko) 2014-12-19 2018-03-14 추가이 세이야쿠 가부시키가이샤 항-c5 항체 및 그의 사용 방법
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
JP2018511557A (ja) 2015-01-22 2018-04-26 中外製薬株式会社 ２種以上の抗ｃ５抗体の組み合わせおよび使用方法
US10330683B2 (en) 2015-02-04 2019-06-25 Genentech, Inc. Mutant smoothened and methods of using the same
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
CN112263677A (zh) 2015-02-26 2021-01-26 默克专利股份公司 用于治疗癌症的pd-1/pd-l1抑制剂
CA2977285A1 (en) 2015-03-16 2016-09-22 F. Hoffmann-La Roche Ag Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
KR20170129902A (ko) 2015-03-23 2017-11-27 조운스 테라퓨틱스, 인크. Icos에 대한 항체
CA2980390A1 (en) 2015-03-23 2016-09-29 Bayer Pharma Aktiengesellschaft Anti-ceacam6 antibodies and uses thereof
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
HK1250373A1 (zh) 2015-04-06 2018-12-14 Acceleron Pharma Inc. Alk7:actriib异多聚体和其用途
HUE057432T2 (hu) 2015-04-07 2022-05-28 Alector Llc Anti-sortilin antitestek és ezek alkalmazási módjai
MX2017012805A (es) 2015-04-07 2018-04-11 Genentech Inc Complejo de unión a antígenos con actividad agonista y métodos de uso.
CN107810197B (zh) 2015-04-24 2022-10-25 豪夫迈·罗氏有限公司 鉴定包含结合多肽的细菌的方法
HK1250997A1 (zh) 2015-05-01 2019-01-18 基因泰克公司 掩蔽抗cd3抗体和使用方法
WO2016179194A1 (en) 2015-05-04 2016-11-10 Jounce Therapeutics, Inc. Lilra3 and method of using the same
HK1248577A1 (zh) 2015-05-11 2018-10-19 F. Hoffmann-La Roche Ag 治疗狼疮性肾炎的组合物和方法
EP3294770B2 (de) 2015-05-12 2024-03-20 F. Hoffmann-La Roche AG Therapeutische und diagnostische verfahren für krebs
EP3297674B1 (de) 2015-05-22 2023-01-04 Translational Drug Development Llc Benzamid- und wirkstoffzusammensetzungen und verfahren zur verwendung
EP3303391A1 (de) 2015-05-26 2018-04-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und pharmazeutische zusammensetzungen (ntsr1-inhibitoren) zur behandlung von hepatozellulären karzinomen
WO2016189118A1 (en) 2015-05-28 2016-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of prognosis and treatment of patients suffering from acute myeloid leukemia
KR20250151554A (ko) 2015-05-29 2025-10-21 제넨테크, 인크. 암에 대한 치료 및 진단 방법
EP3302563A1 (de) 2015-05-29 2018-04-11 H. Hoffnabb-La Roche Ag Humanisierte anti-ebola-virus-glycoprotein-antikörper und verfahren zur verwendung
EP3302552A1 (de) 2015-06-02 2018-04-11 H. Hoffnabb-La Roche Ag Zusammensetzungen und verfahren zur verwendung von anti-il-34-antikörpern zur behandlung von neurologischen erkrankungen
UA126272C2 (uk) 2015-06-05 2022-09-14 Дженентек, Інк. Антитіло проти тау-білка та спосіб його застосування
EP3303399A1 (de) 2015-06-08 2018-04-11 H. Hoffnabb-La Roche Ag Verfahren zur krebsbehandlung mit anti-ox40-antikörpern
US20170000885A1 (en) 2015-06-08 2017-01-05 Genentech, Inc. Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
CA2988982A1 (en) 2015-06-12 2016-12-15 Alector Llc Anti-cd33 antibodies and methods of use thereof
EP3307779A2 (de) 2015-06-12 2018-04-18 Alector LLC Anti-cd33-antikörper und verfahren zur verwendung davon
EP3307780A1 (de) 2015-06-15 2018-04-18 Genentech, Inc. Antikörper und immunkonjugate
EP3916018A1 (de) 2015-06-16 2021-12-01 Genentech, Inc. Anti-cd3-antikörper und verfahren zur verwendung
ES2957567T3 (es) 2015-06-16 2024-01-22 Hoffmann La Roche Anticuerpos humanizados y de afinidad madurada contra FcRH5 y procedimientos de uso
MY193229A (en) 2015-06-16 2022-09-26 Merck Patent GmbH Pd-l1 antagonist combination treatments
TW201718647A (zh) 2015-06-16 2017-06-01 建南德克公司 抗-cll-1抗體及使用方法
ES3043088T3 (en) 2015-06-17 2025-11-24 Hoffmann La Roche Anti-her2 antibodies and methods of use
IL256080B2 (en) 2015-06-17 2025-06-01 Genentech Inc Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
WO2016205567A1 (en) 2015-06-17 2016-12-22 Allakos Inc. Methods and compositions for treating fibrotic diseases
WO2016207094A1 (de) 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit anti-tweakr-antikörpern
EP3313890A1 (de) 2015-06-24 2018-05-02 H. Hoffnabb-La Roche Ag Trispezifische antikörper spezifisch für her2 und ein blut-hirn-schranke-rezeptor und verfahren zur verwendung davon
CN113929779B (zh) 2015-06-24 2025-02-25 豪夫迈·罗氏有限公司 人源化的抗-Tau(pS422)抗体和使用方法
PE20221007A1 (es) 2015-06-24 2022-06-15 Hoffmann La Roche Anticuerpos anti-receptor de transferrina con afinidad disenada
ES2878316T3 (es) 2015-06-29 2021-11-18 Ventana Med Syst Inc Materiales y procedimientos para realizar ensayos histoquímicos de pro-epirregulina y anfirregulina humanas
WO2017004091A1 (en) 2015-06-29 2017-01-05 Genentech, Inc. Type ii anti-cd20 antibody for use in organ transplantation
WO2017024171A1 (en) 2015-08-04 2017-02-09 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
KR102601323B1 (ko) 2015-08-20 2023-11-10 에프. 호프만-라 로슈 아게 페길화 분석물-특이적 결합제를 사용하는 입자-기반 면역어세이
KR20180054639A (ko) 2015-08-28 2018-05-24 알렉터 엘엘씨 항-siglec-7 항체 및 이의 사용 방법
IL258088B2 (en) 2015-09-18 2024-02-01 Chugai Pharmaceutical Co Ltd Antibodies that bind to IL-8 and their uses
WO2017050729A1 (en) 2015-09-22 2017-03-30 Spring Bioscience Corporation Anti-ox40 antibodies and diagnostic uses thereof
CN108137681B (zh) 2015-09-23 2024-06-18 豪夫迈·罗氏有限公司 抗-vegf抗体的优化的变体
RU2757135C2 (ru) 2015-09-24 2021-10-11 АБВИТРО ЭлЭлСи Композиции антител к вич и способы их применения
KR20250021613A (ko) 2015-09-25 2025-02-13 제넨테크, 인크. 항-tigit 항체 및 이의 이용 방법
EP3356551B1 (de) 2015-09-29 2020-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur bestimmung der stoffwechsellage von b-lymphomen
JP2018529719A (ja) 2015-09-30 2018-10-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ａｌｋ陰性がんを処置するためのｐｄ−１系結合アンタゴニストおよびａｌｋ阻害剤の組合せ
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
KR20180073561A (ko) 2015-10-02 2018-07-02 에프. 호프만-라 로슈 아게 이중특이적 항-ceaxcd3 t 세포 활성화 항원 결합 분자
NZ741261A (en) 2015-10-02 2019-11-29 Genentech Inc Pyrrolobenzodiazepine antibody drug conjugates and methods of use
WO2017055542A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
WO2017055393A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
US20170096485A1 (en) 2015-10-02 2017-04-06 Hoffmann-La Roche Inc. Bispecific t cell activating antigen binding molecules
WO2017055385A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
WO2017055395A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
EP3356409A2 (de) 2015-10-02 2018-08-08 H. Hoffnabb-La Roche Ag Bispezifische antigenbindende moleküle zur t-zellen-aktivierung
IL257858B (en) 2015-10-02 2022-09-01 Hoffmann La Roche Anti-pd1 antibodies and methods of use
EP3913000A1 (de) 2015-10-02 2021-11-24 F. Hoffmann-La Roche AG Bispezifische anti-cd19xcd3 bindende antigenmoleküle zur t-zellen-aktivierung
WO2017055392A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
SG10201912150TA (en) 2015-10-06 2020-02-27 Alector Llc Anti-trem2 antibodies and methods of use thereof
US10556953B2 (en) 2015-10-12 2020-02-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Agent capable of depleting CD8 T cells for the treatment of myocardial infarction or acute myocardial infarction
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
WO2017067944A1 (en) 2015-10-19 2017-04-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from triple negative breast cancer
EP3365025B1 (de) 2015-10-20 2020-07-15 Genentech, Inc. Calicheamicin-antikörper-arzneimittelkonjugate und verfahren zur verwendung
KR20180066236A (ko) 2015-10-22 2018-06-18 조운스 테라퓨틱스, 인크. Icos 발현을 계측하기 위한 유전자 특질
US10604577B2 (en) 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
CN116003596A (zh) 2015-10-29 2023-04-25 艾利妥 抗siglec-9抗体及其使用方法
MX2018005036A (es) 2015-10-29 2018-08-01 Hoffmann La Roche Anticuerpos y metodos de uso de anti-regiones de fragmentos cristalizables (fc) variantes.
EP3184547A1 (de) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg-antikörper und verfahren zur verwendung
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
NZ741780A (en) 2015-10-30 2019-11-29 Genentech Inc Anti-htra1 antibodies and methods of use thereof
EP3370754A4 (de) 2015-11-04 2019-10-23 Acceleron Pharma Inc. Verfahren zur erhöhung der erythrozytenkonzentration und behandlung von ineffizienter erythropoiese
CN108602884B (zh) 2015-11-08 2024-06-25 豪夫迈·罗氏有限公司 筛选多特异性抗体的方法
CA3005975A1 (en) 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methods for treating eye disorders
JP7349787B2 (ja) 2015-11-23 2023-09-25 ファイヴ プライム セラピューティクス インク 癌治療におけるｆｇｆｒ２阻害剤単独または免疫刺激剤との組み合わせ
EP3178848A1 (de) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antikörper zur verringerung der bildung von antikörpern gegen medikamente
ES2901794T3 (es) 2015-12-09 2022-03-23 Hoffmann La Roche Anticuerpo anti-CD20 de tipo II para reducir la formación de anticuerpos antifármaco
AR107078A1 (es) 2015-12-18 2018-03-21 Chugai Pharmaceutical Co Ltd Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso
KR102467124B1 (ko) 2015-12-18 2022-11-15 추가이 세이야쿠 가부시키가이샤 항-c5 항체 및 사용 방법
IL299759A (en) 2015-12-30 2023-03-01 Genentech Inc Formulations with reduced polysorbate dissolution
EP3397243A1 (de) 2015-12-30 2018-11-07 H. Hoffnabb-La Roche Ag Verwendung von tryptophanderivaten für proteinformulierungen
WO2017118634A1 (en) 2016-01-04 2017-07-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma
EP3401336A4 (de) 2016-01-05 2020-01-22 Jiangsu Hengrui Medicine Co., Ltd. Pcsk9-antikörper, antigenbindendes fragment davon und medizinische verwendungen davon
WO2017120536A1 (en) 2016-01-08 2017-07-13 Apg Therapeutics, Inc. Polyethylenimine (pei)-polypeptide conjugates and methods of use thereof
AR107303A1 (es) 2016-01-08 2018-04-18 Hoffmann La Roche Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
CA3011739A1 (en) 2016-01-20 2017-07-27 Genentech, Inc. High dose treatments for alzheimer's disease
WO2017129558A1 (en) 2016-01-25 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting or treating myelopoiesis-driven cardiometabolic diseases and sepsis
EP3411396A1 (de) 2016-02-04 2018-12-12 Curis, Inc. Smoothened-mutant und verfahren zur verwendung davon
JP6951826B2 (ja) 2016-02-04 2021-10-20 ザ スクリプス リサーチ インスティテュート ヒト化抗ｃｄ３抗体、その複合体、およびその使用
KR102500659B1 (ko) 2016-02-29 2023-02-16 제넨테크, 인크. 암에 대한 치료 및 진단 방법
WO2017152102A2 (en) 2016-03-04 2017-09-08 Alector Llc Anti-trem1 antibodies and methods of use thereof
US10443054B2 (en) 2016-03-06 2019-10-15 Massachusetts Institute Of Technology Methods for identifying and treating invasive/metastatic breast cancers
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
MX2018010546A (es) 2016-03-15 2019-02-20 Chugai Pharmaceutical Co Ltd Metodos de tratamiento de cancer que usan antagonistas de union al eje de muerte programada 1 (pd-1) y anticuerpos anti glipicano 3 (gpc3).
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
SG11201808085WA (en) 2016-03-22 2018-10-30 Hoffmann La Roche Protease-activated t cell bispecific molecules
EP3433621A1 (de) 2016-03-25 2019-01-30 H. Hoffnabb-La Roche Ag Multiplex-gesamtantikörper- und antikörper-konjugierter arzneimittelquantifizierungstest
EP3231813A1 (de) 2016-03-29 2017-10-18 F. Hoffmann-La Roche AG Trimere kostimulatorische tnf-familien-ligandenhaltige antigenbindende moleküle
US20170306027A1 (en) 2016-04-06 2017-10-26 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
EP3443004A1 (de) 2016-04-14 2019-02-20 H. Hoffnabb-La Roche Ag Anti-rspo3-antikörper und verfahren zur verwendung
CA3019921A1 (en) 2016-04-15 2017-10-19 Genentech, Inc. Methods for monitoring and treating cancer
KR102606938B1 (ko) 2016-04-15 2023-11-29 바이오아트라, 인코퍼레이티드 항 Axl항체 및 이의 면역접합체와 이것들의 용도
EP3443120A2 (de) 2016-04-15 2019-02-20 H. Hoffnabb-La Roche Ag Verfahren zur überwachung und behandlung von krebs
CA3019524A1 (en) 2016-05-02 2017-11-09 F. Hoffmann-La Roche Ag The contorsbody - a single chain target binder
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
EP3243836A1 (de) 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminal-fusionierte antigenbindende moleküle mit ligandentrimer der tnf-familie
JP7285076B2 (ja) 2016-05-11 2023-06-01 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｔｎｆファミリーリガンドトリマーとテネイシン結合部分とを含む抗原結合分子
WO2017194441A1 (en) 2016-05-11 2017-11-16 F. Hoffmann-La Roche Ag Modified anti-tenascin antibodies and methods of use
EP3455261B1 (de) 2016-05-13 2022-08-03 BioAtla, Inc. Anti-ror2-antikörper, antikörperfragmente, deren immunkonjugate und verwendungen davon
EP3243832A1 (de) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigenbindende moleküle mit einem ligandentrimer der tnf-familie und pd1-bindungsteil
CN118436801A (zh) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
BR112018073920A2 (pt) 2016-05-26 2019-02-26 Merck Patent Gmbh inibidores de pd-1/pd-l1 para tratamento de câncer".
US20170370906A1 (en) 2016-05-27 2017-12-28 Genentech, Inc. Bioanalytical analysis of site-specific antibody drug conjugates
WO2017202890A1 (en) 2016-05-27 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating myeloma
EP3252078A1 (de) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Typ ii anti-cd20 antikörper und anti-cd20/cd3 bispecific antikörper zur behandlung von krebs
CA3059010A1 (en) 2016-06-02 2018-12-06 F. Hoffmann-La Roche Ag Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
IL262996B2 (en) 2016-06-06 2024-03-01 Hoffmann La Roche Fusion proteins for ophthalmology with increased eye retention
EP3464280B1 (de) 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Silvestrol-antikörper-arzneimittelkonjugate und verfahren zur verwendung
KR102306744B1 (ko) 2016-06-17 2021-09-28 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체 및 사용 방법
WO2017218891A1 (en) 2016-06-17 2017-12-21 Life Technologies Corporation Site-specific crosslinking of antibodies
CN109563160B (zh) 2016-06-24 2023-02-28 豪夫迈·罗氏有限公司 抗聚泛素多特异性抗体
EP3475700A4 (de) 2016-06-26 2020-03-04 Gennova Biopharmaceuticals Limited Antikörper-phagendisplay-bibliothek
EP3478717B1 (de) 2016-07-04 2022-01-05 F. Hoffmann-La Roche AG Neuartiges antikörperformat
RU2748278C2 (ru) 2016-07-15 2021-05-21 Акселерон Фарма Инк. Композиции и способы лечения легочной гипертензии
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
EA201990226A1 (ru) 2016-07-27 2019-08-30 Акселерон Фарма Инк. Способы и композиции для лечения миелофиброза
MA45784A (fr) 2016-07-29 2019-06-05 Juno Therapeutics Inc Anticorps anti-idiotypes dirigés contre anti-cd19 anticorps
EP3494143B1 (de) 2016-08-03 2022-10-05 Cipla USA, Inc. Plazomicin-antikörper und verfahren zur verwendung
EP3494139B1 (de) 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalente und multiepitopische anitikörper mit agonistischer wirkung und verfahren zur verwendung
CN109689099B (zh) 2016-08-05 2023-02-28 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
CN109476748B (zh) 2016-08-08 2023-05-23 豪夫迈·罗氏有限公司 用于癌症的治疗和诊断方法
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
BR112019002036A2 (pt) 2016-08-12 2019-05-14 Genentech Inc métodos de tratamento de um sujeito com câncer colorretal, kit para tratamento do câncer colorretal em um sujeito humano e combinação de fármacos para a terapia do câncer colorretal
US11168148B2 (en) 2016-09-07 2021-11-09 The Regents Of The University Of California Antibodies to oxidation-specific epitopes
WO2018049261A1 (en) 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus expressing immune checkpoint modulators
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
WO2018050878A1 (en) 2016-09-19 2018-03-22 F. Hoffmann-La Roche Ag Complement factor based affinity chromatography
CA3031589C (en) 2016-09-23 2025-05-06 Genentech, Inc. USES OF IL-13 ANTAGONISTS FOR THE TREATMENT OF ATOPIC DERMATITIS
CN109862917A (zh) 2016-09-29 2019-06-07 基因泰克公司 Mek抑制剂,pd-1轴抑制剂,和紫杉烷的组合疗法
JP7022123B2 (ja) 2016-09-30 2022-02-17 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｃｄ３に対する二重特異性抗体
JP7050770B2 (ja) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗体薬物コンジュゲートの調製方法
US11976111B2 (en) 2016-10-05 2024-05-07 Acceleron Pharma Inc. ActRIIa and ALK4 polypeptides for treating kidney fibrosis, inflammation and injury
AU2017339856B2 (en) 2016-10-06 2024-09-05 Merck Patent Gmbh Dosing regimen of avelumab for the treatment of cancer
IL265759B2 (en) 2016-10-06 2025-10-01 Genentech Inc Therapeutic and diagnostic methods for cancer
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
CN110121509B (zh) 2016-10-26 2024-05-07 西达-赛奈医疗中心 中和抗tl1a单克隆抗体
WO2018081531A2 (en) 2016-10-28 2018-05-03 Ariad Pharmaceuticals, Inc. Methods for human t-cell activation
JP2020500508A (ja) 2016-10-28 2020-01-16 バンヤン・バイオマーカーズ・インコーポレーテッド ユビキチンｃ末端ヒドロラーゼｌ１（ｕｃｈ−ｌ１）およびグリア線維酸性タンパク質（ｇｆａｐ）に対する抗体および関連する方法
JP2019535250A (ja) 2016-10-29 2019-12-12 ジェネンテック， インコーポレイテッド 抗ｍｉｃ抗体及び使用方法
HRP20211703T1 (hr) 2016-11-02 2022-02-04 Jounce Therapeutics, Inc. Protutijela protiv pd-1 i njihova upotreba
WO2018144097A1 (en) 2016-11-04 2018-08-09 Akeagen Llc Genetically modified non-human animals and methods for producing heavy chain-only antibodies
US11466094B2 (en) 2016-11-15 2022-10-11 Genentech, Inc. Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
CN110234319B (zh) 2016-11-23 2022-09-27 转化药物开发有限责任公司 苯甲酰胺和活性化合物的组合物及其使用方法
WO2018100190A1 (en) 2016-12-02 2018-06-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for diagnosing renal cell carcinoma
MX2019006334A (es) 2016-12-07 2019-08-01 Genentech Inc Anticuerpos antitau y métodos de uso.
CA3045294A1 (en) 2016-12-07 2018-06-14 Genentech, Inc. Anti-tau antibodies and methods of use
BR112018016717A2 (pt) 2016-12-16 2018-12-26 H Lundbeck As agentes, usos e métodos
IL267284B2 (en) 2016-12-19 2023-03-01 Hoffmann La Roche Combination therapy with a targeted 4-bb1 agonist (cd137)
KR102692708B1 (ko) 2016-12-20 2024-08-07 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법
WO2018114879A1 (en) 2016-12-21 2018-06-28 F. Hoffmann-La Roche Ag Method for in vitro glycoengineering of antibodies
CN110100007B (zh) 2016-12-21 2024-05-28 豪夫迈·罗氏有限公司 用于体外糖工程化抗体的酶的再使用
CA3044920C (en) 2016-12-21 2022-06-28 Roberto Falkenstein In vitro glycoengineering of antibodies
WO2018141768A1 (en) 2017-02-02 2018-08-09 Roche Diagnostics Gmbh Immunoassay using at least two pegylated analyte-specific binding agents
CN110494453B (zh) 2017-02-10 2023-05-26 豪夫迈·罗氏有限公司 抗类胰蛋白酶抗体、其组合物及其用途
PL3589754T3 (pl) 2017-03-01 2023-10-09 F. Hoffmann-La Roche Ag Sposoby diagnostyczne i terapeutyczne w chorobach nowotworowych
EP3600441A1 (de) 2017-03-22 2020-02-05 Genentech, Inc. Hydrogelvernetzte hyaluronsäure-prodrug-zusammensetzungen und verfahren
AR111249A1 (es) 2017-03-22 2019-06-19 Genentech Inc Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares
EP3600427A1 (de) 2017-03-24 2020-02-05 INSERM - Institut National de la Santé et de la Recherche Médicale Verfahren und zusammensetzungen zur behandlung von melanom
WO2018178030A1 (en) 2017-03-27 2018-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases
WO2018178029A1 (en) 2017-03-27 2018-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases
EP3601337A1 (de) 2017-03-28 2020-02-05 Genentech, Inc. Verfahren zur behandlung neurodegenerativer erkrankungen
WO2018178074A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Trimeric antigen binding molecules specific for a costimulatory tnf receptor
WO2018178076A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
WO2018178055A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
MX2019011657A (es) 2017-03-30 2019-11-18 Merck Patent Gmbh Combinacion de un anticuerpo anti ligando 1 de muerte programada (pd-l1) e inhibidor de proteina cinasa dependiente de acido desoxirribonucleico (dna-pk) para tratamiento de cancer.
WO2018178237A1 (en) 2017-03-30 2018-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of mitochondrial genetic diseases
EP3606947B1 (de) 2017-04-03 2022-12-21 F. Hoffmann-La Roche AG Immunokonjugat von il-2 mit einem bispezifischen antikörper gerichtet gegen pd-1 und tim-3
AU2018247767B2 (en) 2017-04-03 2025-01-30 F. Hoffmann-La Roche Ag Antibodies binding to STEAP-1
WO2018187191A1 (en) 2017-04-03 2018-10-11 Jounce Therapeutics, Inc Compositions and methods for the treatment of cancer
KR20190121816A (ko) 2017-04-03 2019-10-28 에프. 호프만-라 로슈 아게 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
HUE060019T2 (hu) 2017-04-05 2023-01-28 Hoffmann La Roche Anti-LAG3 antitestek
JP2020516638A (ja) 2017-04-13 2020-06-11 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんを処置する方法における使用のための、インターロイキン２イムノコンジュゲート、ｃｄ４０アゴニスト、および任意選択のｐｄ−１軸結合アンタゴニスト
EP3624820A1 (de) 2017-04-21 2020-03-25 H. Hoffnabb-La Roche Ag Verwendung von klk5-antagonisten zur behandlung einer krankheit
SG10201913677SA (en) 2017-04-27 2020-03-30 Tesaro Inc Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
EA201992626A1 (ru) 2017-05-05 2020-04-24 Аллакос Инк. Способы и композиции для лечения аллергических заболеваний глаз
EP3401328A1 (de) 2017-05-10 2018-11-14 Bayer Pharma Aktiengesellschaft Einstufige antikörperhumanisierung durch mischung der rahmenregionen einer golden-gate-basierten keimbahn
US11168129B2 (en) 2017-05-15 2021-11-09 University Of Rochester Broadly neutralizing anti-influenza human monoclonal antibody and uses thereof
WO2018213304A1 (en) 2017-05-16 2018-11-22 Five Prime Therapeutics, Inc. Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
US11359014B2 (en) 2017-05-16 2022-06-14 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
WO2019002548A1 (en) 2017-06-29 2019-01-03 INSERM (Institut National de la Santé et de la Recherche Médicale) TREATMENT OF MIGRAINE WITH TREK1, TREK2 AGONIZATION OR HETEROMERS COMPRISING SAME
WO2019016310A1 (en) 2017-07-20 2019-01-24 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND COMPOSITIONS FOR TREATING CANCERS
CN111492245A (zh) 2017-07-21 2020-08-04 基因泰克公司 癌症的治疗和诊断方法
JP6889328B2 (ja) 2017-07-31 2021-06-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 三次元構造に基づくヒト化方法
MD3601358T2 (ro) 2017-08-03 2023-10-31 Alector Llc Anticorpi anti-TREM2 și metode de utilizare a acestora
AU2018310985A1 (en) 2017-08-03 2019-11-07 Alector Llc Anti-CD33 antibodies and methods of use thereof
EP3444275A1 (de) 2017-08-16 2019-02-20 Exiris S.r.l. Monoklonaler antikörper anti-fgfr4
EP3675906A4 (de) 2017-08-28 2021-05-26 Angiex, Inc. Anti-tm4sf1-antikörper und verfahren zu deren verwendung
US20200216542A1 (en) 2017-09-20 2020-07-09 Chugai Seiyaku Kabushiki Kaisha Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
TW202423960A (zh) 2017-09-29 2024-06-16 日商中外製藥股份有限公司 具有第viii凝血因子(fviii)輔因子機能替代活性的多重特異性抗原結合分子及含有此分子作為有效成分之藥學製劑
AU2018347521A1 (en) 2017-10-12 2020-05-07 Immunowake Inc. VEGFR-antibody light chain fusion protein
WO2019083904A1 (en) 2017-10-23 2019-05-02 Chan Zuckerberg Biohub, Inc. AFUCOSYLATED IGG FC GLYCANES MEASUREMENT AND METHODS OF TREATMENT THEREOF
US11897969B2 (en) 2017-10-26 2024-02-13 The Regents Of The University Of California Inhibition of oxidation-specific epitopes to treat ischemic reperfusion injury
CN111315781A (zh) 2017-11-01 2020-06-19 豪夫迈·罗氏有限公司 用靶向性ox40激动剂的组合疗法
MX2020004196A (es) 2017-11-01 2020-11-09 Hoffmann La Roche Trifab-contorsbody.
JP2021500930A (ja) 2017-11-01 2021-01-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｏｍｐボディ−多価標的結合物質
WO2019090263A1 (en) 2017-11-06 2019-05-09 Genentech, Inc. Diagnostic and therapeutic methods for cancer
EP3710589A4 (de) 2017-11-14 2021-11-10 Chugai Seiyaku Kabushiki Kaisha Anti-c1s-antikörper und verfahren zur verwendung
EP3502140A1 (de) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Kombinationstherapie von tumorabgezielten icos-agonisten mit t-zellenbispezifischen molekülen
EP3728317A2 (de) 2017-12-21 2020-10-28 F. Hoffmann-La Roche AG An hla-a2/wt1 bindende antikörper
JP7391868B2 (ja) 2017-12-22 2023-12-05 ジョウンセ セラピューティクス， インク． Ｌｉｌｒｂ２に対する抗体
TW201929907A (zh) 2017-12-22 2019-08-01 美商建南德克公司 Pilra結合劑用於治療疾病之用途
AU2018396970B2 (en) 2017-12-28 2025-09-25 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against TIGIT
CN111542543B (zh) 2017-12-28 2023-12-22 南京传奇生物科技有限公司 针对pd-l1的抗体及其变体
US11440957B2 (en) 2017-12-29 2022-09-13 Alector Llc Anti-TMEM106B antibodies and methods of use thereof
WO2019134946A1 (en) 2018-01-04 2019-07-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma resistant
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
CN111699200B (zh) 2018-01-15 2023-05-26 南京传奇生物科技有限公司 针对pd-1的单域抗体和其变体
EP3740505A1 (de) 2018-01-16 2020-11-25 Lakepharma Inc. Bispezifischer antikörper, der cd3 und ein anderes ziel bindet
JP7268038B2 (ja) 2018-01-31 2023-05-02 アレクトル エルエルシー 抗ｍｓ４ａ４ａ抗体及びその使用方法
CN118772287A (zh) 2018-02-08 2024-10-15 豪夫迈·罗氏有限公司 双特异性抗原结合分子和使用方法
EP3749362A1 (de) 2018-02-09 2020-12-16 F. Hoffmann-La Roche AG Therapeutische und diagnostische verfahren für mastzellvermittelte entzündliche erkrankungen
WO2019157342A1 (en) 2018-02-09 2019-08-15 Acceleron Pharma Inc. Methods for treating heterotopic ossification
TWI829667B (zh) 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體
JP7384811B2 (ja) 2018-02-16 2023-11-21 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 白斑を処置するための方法及び組成物
MX2020008882A (es) 2018-02-26 2021-01-08 Genentech Inc Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
EP3759492A1 (de) 2018-02-27 2021-01-06 ECS-Progastrin SA Progastrin als biomarker für immuntherapie
IL277174B2 (en) 2018-03-13 2025-12-01 Hoffmann La Roche Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies
TWI841551B (zh) 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
IL277375B2 (en) 2018-03-15 2025-08-01 Chugai Pharmaceutical Co Ltd Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
JP2021519073A (ja) 2018-03-29 2021-08-10 ジェネンテック， インコーポレイテッド 哺乳動物細胞におけるラクトジェニック活性の制御
AU2019241350B2 (en) 2018-03-30 2025-10-02 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against LAG-3 and uses thereof
WO2019192432A1 (zh) 2018-04-02 2019-10-10 上海博威生物医药有限公司 结合淋巴细胞活化基因-3(lag-3)的抗体及其用途
TW202011029A (zh) 2018-04-04 2020-03-16 美商建南德克公司 偵測及定量fgf21之方法
CN112334485B (zh) 2018-04-06 2024-09-27 百进生物科技公司 抗-四次穿膜蛋白33药剂及其组合物以及制备和使用方法
EP3552631A1 (de) 2018-04-10 2019-10-16 Inatherys Antikörper-arzneimittel-konjugate und deren verwendungen zur behandlung von krebs
WO2019197600A1 (en) 2018-04-13 2019-10-17 F. Hoffmann-La Roche Ag Her2-targeting antigen binding molecules comprising 4-1bbl
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
AR115052A1 (es) 2018-04-18 2020-11-25 Hoffmann La Roche Anticuerpos multiespecíficos y utilización de los mismos
MA52366A (fr) 2018-04-25 2021-03-03 Prometheus Biosciences Inc Anticorps anti-tl1a optimisés
WO2019213384A1 (en) 2018-05-03 2019-11-07 University Of Rochester Anti-influenza neuraminidase monoclonal antibodies and uses thereof
BR112020022145A2 (pt) 2018-05-04 2021-01-26 Merck Patent Gmbh inibição combinada de pd-1/pd-l1, tgfbeta e dna-pk para o tratamento de câncer
TW202448946A (zh) 2018-05-25 2024-12-16 美商阿列克特有限責任公司 抗-sirpa 抗體及其使用方法
EP3818085A4 (de) 2018-06-01 2022-03-09 Tayu Huaxia Biotech Medical Group Co., Ltd. Zusammensetzungen und deren verwendungen zur behandlung von erkrankungen oder störungen
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
JP7372237B2 (ja) 2018-06-04 2023-10-31 中外製薬株式会社 細胞質内での半減期が変化した抗原結合分子
TW202519270A (zh) 2018-06-07 2025-05-16 美商思進公司 喜樹鹼結合物
KR20210030341A (ko) 2018-06-08 2021-03-17 알렉터 엘엘씨 항-Siglec-7 항체 및 그의 사용 방법
CA3103265A1 (en) 2018-06-12 2019-12-19 Angiex, Inc. Antibody-oligonucleotide conjugates
AU2019288728A1 (en) 2018-06-23 2021-01-14 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
CN112384532B (zh) 2018-06-29 2025-01-10 艾利妥 抗SIRP-β1抗体及其使用方法
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
RS64034B1 (sr) 2018-07-13 2023-04-28 Alector Llc Anti-sortilin antitela i načini njihove upotrebe
US20210275589A1 (en) 2018-07-13 2021-09-09 Nanjing Legend Biotech Co. Ltd. Co-receptor systems for treating infectious diseases
BR112021000673A2 (pt) 2018-07-18 2021-04-20 Genentech, Inc. métodos para tratar um indivíduo com câncer de pulmão, kits, anticorpo anti-pd-l1 e composições
KR20210049106A (ko) 2018-07-27 2021-05-04 알렉터 엘엘씨 항-siglec-5 항체 및 이의 사용 방법
IL280525B2 (en) 2018-08-08 2024-11-01 Genentech Inc Use of tryptophan derivatives and l-methionine for protein formulation
KR102697702B1 (ko) 2018-08-10 2024-08-22 추가이 세이야쿠 가부시키가이샤 항cd137 항원 결합 분자 및 그의 사용
BR112021002164A2 (pt) 2018-08-13 2021-08-03 Inhibrx, Inc. polipeptídeos de ligação a ox40 e usos dos mesmos
WO2020037258A1 (en) 2018-08-17 2020-02-20 Ab Studio Inc. Catabodies and methods of use thereof
TW202021618A (zh) 2018-08-17 2020-06-16 美商２３與我有限公司 抗ｉｌ１ｒａｐ抗體及其使用方法
CN112566936B (zh) 2018-08-21 2024-07-12 阿尔伯特爱因斯坦医学院 针对人tim-3的单克隆抗体
US12377294B2 (en) 2018-08-28 2025-08-05 Ambrx, Inc. Anti-CD3 antibody folate bioconjugates and their uses
SG11202101552SA (en) 2018-08-31 2021-03-30 Alector Llc Anti-cd33 antibodies and methods of use thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
US12460000B2 (en) 2018-09-07 2025-11-04 Itabmed (Hk) Limited Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
WO2020053125A1 (en) 2018-09-10 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of neurofibromatosis
CN112673022B (zh) 2018-09-10 2024-07-09 南京传奇生物科技有限公司 针对cd33的单结构域抗体及其构建体
CN112955747A (zh) 2018-09-19 2021-06-11 豪夫迈·罗氏有限公司 膀胱癌的治疗和诊断方法
MX2021003213A (es) 2018-09-21 2021-05-12 Genentech Inc Metodos de diagnostico para cancer de mama triple negativo.
EP3856343A1 (de) 2018-09-25 2021-08-04 Biolegend, Inc. Anti-tlr9-mittel und zusammensetzungen sowie verfahren zu ihrer herstellung und verwendung
BR112021004935A2 (pt) 2018-09-26 2021-06-01 Merck Patent Gmbh combinação de antagonista de pd-1, inibidor de atr e agente de platinação para tratamento de câncer
TW202028244A (zh) 2018-10-09 2020-08-01 美商建南德克公司 用於確定突觸形成之方法及系統
US20210340273A1 (en) 2018-10-11 2021-11-04 Inhlbrx, inc. 5t4 single domain antibodies and therapeutic compositions thereof
CA3115082A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. B7h3 single domain antibodies and therapeutic compositions thereof
WO2020076977A2 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
EP3864049A1 (de) 2018-10-11 2021-08-18 Inhibrx, Inc. Pd-1-einzeldomänen-antikörper und therapeutische zusammensetzungen davon
EP3866785A1 (de) 2018-10-15 2021-08-25 Merck Patent GmbH Kombinationstherapie unter verwendung von dna-alkylierenden mitteln und atr-inhibitoren
EP3867646A1 (de) 2018-10-18 2021-08-25 F. Hoffmann-La Roche AG Diagnostische und therapeutische verfahren für sarkomatoiden nierenkrebs
WO2020086858A1 (en) 2018-10-24 2020-04-30 Genentech, Inc. Conjugated chemical inducers of degradation and methods of use
KR102467349B1 (ko) 2018-10-29 2022-11-16 에프. 호프만-라 로슈 아게 항체 제형
US20210395390A1 (en) 2018-10-31 2021-12-23 Bayer Aktiengesellschaft Reversal agents for neutralizing the therapeutic activity of anti-fxia antibodies
CA3118453A1 (en) 2018-11-02 2020-05-07 The Regents Of The University Of California Compositions and methods for treating brain injury
EP3877407B1 (de) 2018-11-05 2026-03-11 F. Hoffmann-La Roche AG Verfahren zur herstellung von zwei kettenproteinen in prokaryotischen wirtszellen
CN113330034A (zh) 2018-11-16 2021-08-31 阿尔伯特爱因斯坦医学院 针对B7-H3的IgV结构域的单克隆抗体及其用途
WO2020104479A1 (en) 2018-11-20 2020-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
CA3121699A1 (en) 2018-12-05 2020-06-11 Morphosys Ag Multispecific antigen-binding molecules
AU2018451747A1 (en) 2018-12-06 2021-06-17 F. Hoffmann-La Roche Ag Combination therapy of diffuse large B-cell lymphoma comprising an anti-CD79b immunoconjugates, an alkylating agent and an anti-CD20 antibody
WO2020115261A1 (en) 2018-12-07 2020-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
EP3894427A1 (de) 2018-12-10 2021-10-20 Genentech, Inc. Photovernetzende peptide zur stellenspezifischen konjugation an fc-haltige proteine
GB201820547D0 (en) 2018-12-17 2019-01-30 Oxford Univ Innovation Modified antibodies
GB201820554D0 (en) 2018-12-17 2019-01-30 Univ Oxford Innovation Ltd BTLA antibodies
AR117327A1 (es) 2018-12-20 2021-07-28 23Andme Inc Anticuerpos anti-cd96 y métodos de uso de estos
EP3898667A2 (de) 2018-12-20 2021-10-27 F. Hoffmann-La Roche AG Modifizierter antikörper fcs und verwendungsverfahren
WO2020132231A1 (en) 2018-12-21 2020-06-25 Genentech, Inc. Methods of producing polypeptides using a cell line resistant to apoptosis
EP3898677A1 (de) 2018-12-21 2021-10-27 OSE Immunotherapeutics Bifunktionelles anti-pd-1/il-7-molekül
JP2022513495A (ja) 2018-12-21 2022-02-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 腫瘍標的化スーパーアゴニストｃｄ２８抗原結合分子
TWI829831B (zh) 2018-12-21 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合cd3之抗體
WO2020127885A1 (en) 2018-12-21 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for treating cancers and resistant cancers
CN113573782B (zh) 2018-12-21 2025-12-16 Ose免疫疗法公司 针对人pd-1的双功能分子
WO2020127618A1 (en) 2018-12-21 2020-06-25 F. Hoffmann-La Roche Ag Tumor-targeted agonistic cd28 antigen binding molecules
EP3898673A1 (de) 2018-12-21 2021-10-27 23Andme, Inc. Anti-il-36-antikörper und verfahren zur verwendung davon
KR20210107062A (ko) 2018-12-21 2021-08-31 오제 이뮈노테라프틱스 이작용성 항-PD-1/SIRPα 분자
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
KR20210141447A (ko) 2018-12-26 2021-11-23 실리오 디벨럽먼트, 인크. 항-ctla4 항체 및 이의 사용 방법
WO2020141145A1 (en) 2018-12-30 2020-07-09 F. Hoffmann-La Roche Ag Anti-rabbit cd19 antibodies and methods of use
AR117770A1 (es) 2019-01-07 2021-08-25 Inhibrx Inc Polipéptidos que comprenden polipéptidos con il-2 modificada y usos de los mismos
MX2021008434A (es) 2019-01-14 2021-09-23 Genentech Inc Metodos para tratar el cancer con un antagonista de union al eje de pd-1 y una vacuna de arn.
CA3126778A1 (en) 2019-01-17 2020-07-23 Bayer Aktiengesellschaft Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
CA3126359A1 (en) 2019-01-22 2020-07-30 Genentech, Inc. Immunoglobulin a antibodies and methods of production and use
CN113795511B (zh) 2019-01-23 2024-07-23 大有华夏生物医药集团有限公司 抗pd-l1双抗体及其用途
EP3915581A4 (de) 2019-01-24 2023-03-22 Chugai Seiyaku Kabushiki Kaisha Neuartige krebsantigene und antikörper dieser antigene
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
EP3921031A1 (de) 2019-02-04 2021-12-15 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren und zusammensetzungen zur modulation der blut-gehirn-schranke
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
EP3927744A1 (de) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Multifunktionelle moleküle, die an t-zell-verwandte krebszellen binden, und verwendungen davon
GB2597851B (en) 2019-02-21 2024-05-29 Marengo Therapeutics Inc Antibody molecules that bind to NKP30 and uses thereof
BR112021016923A2 (pt) 2019-02-27 2021-11-03 Genentech Inc Métodos para tratar um paciente com câncer hematológico, métodos para tratar um paciente com mm recidivante ou refratário, métodos para tratar um paciente tendo um lnh recidivante ou refratário e kits
JP2022522007A (ja) 2019-02-27 2022-04-13 アンジーエックス・インコーポレーテッド 抗ｔｍ４ｓｆ１抗体を含む抗体薬物コンジュゲートおよびそれを使用する方法
MX2021010441A (es) 2019-03-01 2021-09-21 Allogene Therapeutics Inc Receptores antigenicos quimericos y agentes de union dirigidos a dll3.
EP3935385A1 (de) 2019-03-08 2022-01-12 F. Hoffmann-La Roche AG Verfahren zur detektion und quantifizierung von membranassoziierten proteinen auf extrazellulären vesikeln
MX2021010996A (es) 2019-03-14 2021-11-04 Genentech Inc Tratamiento de cancer con anticuerpos biespecificos contra her2xcd3 en combinacion con mab anti-her2.
CN119899260A (zh) 2019-03-19 2025-04-29 阿尔伯特爱因斯坦医学院 用于预防和治疗单纯疱疹病毒感染的单克隆抗体
CA3130701A1 (en) 2019-03-21 2020-09-24 Yajin Ni Methods for enhancing tcr.alpha..beta.+cell depletion efficiency
EP3946330A1 (de) 2019-03-29 2022-02-09 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren zur behandlung von keloid, hypertrophischen narben und/oder hyperpigmentierungserkrankungen
EP3952996A1 (de) 2019-04-12 2022-02-16 F. Hoffmann-La Roche AG Bispezifische antigenbindende moleküle mit lipocalinmuteinen
MX2021012692A (es) 2019-04-19 2021-11-12 Genentech Inc Anticuerpos anti-mertk y sus metodos de uso.
WO2020219812A1 (en) 2019-04-26 2020-10-29 Allogene Therapeutics, Inc. Methods of manufacturing allogeneic car t cells
WO2020221796A1 (en) 2019-04-30 2020-11-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
TWI879768B (zh) 2019-05-03 2025-04-11 美商建南德克公司 用抗pd-l1抗體治療癌症之方法
KR20220004750A (ko) 2019-05-04 2022-01-11 인히브릭스, 인크. Cd33 결합 폴리펩타이드 및 이의 용도
BR112021020999A2 (pt) 2019-05-04 2021-12-14 Inhibrx Inc Polipeptídeos de ligação à clec12a e usos dos mesmos
AU2020269268A1 (en) 2019-05-04 2021-11-11 Inhibrx Biosciences, Inc. CD123-binding polypeptides and uses thereof
KR20220007136A (ko) 2019-05-14 2022-01-18 제넨테크, 인크. 소포 림프종을 치료하기 위한 항-CD79b 면역접합체의 사용 방법
BR112021021689A2 (pt) 2019-05-15 2022-03-22 Chugai Pharmaceutical Co Ltd Molécula de ligação a antígeno, composição farmacêutica, e método
US20200369759A1 (en) 2019-05-23 2020-11-26 Fibrogen, Inc. Methods of treatment of muscular dystrophies
KR102919581B1 (ko) 2019-06-11 2026-01-30 알렉터 엘엘씨 치료요법에 사용하기 위한 항-소르틸린 항체
WO2020260329A1 (en) 2019-06-26 2020-12-30 F. Hoffmann-La Roche Ag Fusion of an antibody binding cea and 4-1bbl
EP3990492A1 (de) 2019-06-27 2022-05-04 F. Hoffmann-La Roche AG Neuartige icos-antikörper und tumorspezifische antigenbindende moleküle damit
IL289219B2 (en) 2019-06-28 2025-06-01 Genentech Inc Composition and methods for stabilizing liquid protein formulations
WO2021001289A1 (en) 2019-07-02 2021-01-07 F. Hoffmann-La Roche Ag Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
AR119393A1 (es) 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
CN114072427B (zh) 2019-07-17 2024-04-26 南京传奇生物科技有限公司 抗dll3嵌合抗原受体及其用途
SG11202112491WA (en) 2019-07-31 2021-12-30 Hoffmann La Roche Antibodies binding to gprc5d
WO2021018925A1 (en) 2019-07-31 2021-02-04 F. Hoffmann-La Roche Ag Antibodies binding to gprc5d
BR112022001733A2 (pt) 2019-07-31 2022-06-28 Alector Llc Anticorpos anti-ms4a4a e métodos de uso dos mesmos
JP7181438B2 (ja) 2019-08-06 2022-11-30 アプリノイア セラピューティクス リミテッド 病理学的タウ種に結合する抗体及びその使用
US12098212B2 (en) 2019-08-12 2024-09-24 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
CA3150807A1 (en) 2019-09-04 2021-03-11 Y-Biologics Inc. Anti-vsig4 antibody or antigen binding fragment and uses thereof
WO2021048292A1 (en) 2019-09-11 2021-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
CA3146616A1 (en) 2019-09-12 2021-03-18 Matthew Dominic CASCINO Compositions and methods of treating lupus nephritis
CN114423791B (zh) 2019-09-18 2026-01-09 豪夫迈·罗氏有限公司 抗klk7抗体、抗klk5抗体、多特异性抗klk5/klk7抗体及使用方法
MX2022003266A (es) 2019-09-20 2022-04-11 Genentech Inc Dosis para anticuerpos anti-triptasa.
TW202126690A (zh) 2019-09-27 2021-07-16 美商建南德克公司 用抗ｔｉｇｉｔ和抗ｐｄ－ｌ１拮抗劑抗體給藥治療
CN114829401A (zh) 2019-09-27 2022-07-29 南京金斯瑞生物科技有限公司 抗vhh域抗体及其用途
CN114746119A (zh) 2019-09-27 2022-07-12 詹森生物科技公司 抗-ceacam抗体及其用途
WO2021063968A1 (en) 2019-09-30 2021-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and composition for diagnosing chronic obstructive pulmonary disease
US20220354811A1 (en) 2019-10-03 2022-11-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for modulating macrophages polarization
WO2021076196A1 (en) 2019-10-18 2021-04-22 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
PH12022550978A1 (en) 2019-10-24 2023-10-09 Cedars Sinai Medical Center Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
CA3154413A1 (en) 2019-11-01 2021-05-06 Yan Lan Combined inhibition of pd-1, tgf.beta. and atm together with radiotherapy for the treatment of cancer
IL292757A (en) 2019-11-05 2022-07-01 Merck Patent Gmbh Anti-tigit antibodies and uses thereof
IL292758A (en) 2019-11-05 2022-07-01 Merck Patent Gmbh Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer
CN115066613A (zh) 2019-11-06 2022-09-16 基因泰克公司 用于治疗血液癌症的诊断和治疗方法
TWI895295B (zh) 2019-11-12 2025-09-01 美商方得生醫療公司 偵測編碼新生抗原之融合基因之方法
CN114641270A (zh) 2019-11-15 2022-06-17 豪夫迈·罗氏有限公司 防止水性蛋白质溶液中可见颗粒的形成
CN115003699A (zh) 2019-12-05 2022-09-02 艾利妥 抗trem2抗体的使用方法
IL293430A (en) 2019-12-06 2022-07-01 Juno Therapeutics Inc Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods
CN115335399A (zh) 2019-12-06 2022-11-11 朱诺治疗学股份有限公司 针对gprc5d靶结合结构域的抗独特型抗体以及相关组合物和方法
CN114787191A (zh) 2019-12-09 2022-07-22 基因泰克公司 抗pd-l1抗体制剂
MX2022007156A (es) 2019-12-12 2022-09-07 Alector Llc Metodos de uso de anticuerpos anti-cd33.
AU2020401319A1 (en) 2019-12-13 2022-06-30 Alector Llc Anti-MerTK antibodies and methods of use thereof
PE20221511A1 (es) 2019-12-13 2022-10-04 Genentech Inc Anticuerpos anti-ly6g6d y metodos de uso
KR20220100963A (ko) 2019-12-18 2022-07-18 에프. 호프만-라 로슈 아게 Hla-a2/mage-a4에 결합하는 항체
AU2020412609A1 (en) 2019-12-23 2022-06-16 Genentech, Inc. Apolipoprotein L1-specific antibodies and methods of use
EP4082570B1 (de) 2019-12-27 2026-02-25 Chugai Seiyaku Kabushiki Kaisha Anti-ctla-4-antikörper und verwendung davon
EP4084823A4 (de) 2020-01-03 2024-05-15 Marengo Therapeutics, Inc. Anti-tcr-antikörpermoleküle und ihre verwendungen
EP4087866A1 (de) 2020-01-09 2022-11-16 F. Hoffmann-La Roche AG Neue 4-1bbl-trimer-haltige antigenbindende moleküle
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
WO2021144426A1 (en) 2020-01-17 2021-07-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
JP2023511595A (ja) 2020-01-27 2023-03-20 ジェネンテック， インコーポレイテッド 抗ｔｉｇｉｔアンタゴニスト抗体を用いたがんを処置するための方法
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2022050954A1 (en) 2020-09-04 2022-03-10 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
KR20220148175A (ko) 2020-01-29 2022-11-04 인히브릭스, 인크. Ｃｄ28 단일 도메인 항체 및 이의 다가 및 다중특이적 구조체
EP4096708A1 (de) 2020-01-31 2022-12-07 Genentech, Inc. Verfahren zur induktion neoepitopspezifischer t-zellen mit einem pd-1-achsenbindenden antagonisten und einem rna-impfstoff
CN115427453B (zh) 2020-02-10 2024-07-12 上海诗健生物科技有限公司 Cldn18.2抗体及其用途
KR102929927B1 (ko) 2020-02-10 2026-02-25 상하이 에스쿠겐 바이오테크놀로지 컴퍼니 리미티드 클라우딘18.2 항체 및 그것의 사용
TWI895351B (zh) 2020-02-12 2025-09-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
IL295023A (en) 2020-02-14 2022-09-01 Jounce Therapeutics Inc Antibodies and fusion proteins that bind to ccr8 and their uses
US20230159637A1 (en) 2020-02-24 2023-05-25 Alector Llc Methods of use of anti-trem2 antibodies
WO2021173889A1 (en) 2020-02-26 2021-09-02 Ambrx, Inc. Uses of anti-cd3 antibody folate bioconjugates
CN115151573A (zh) 2020-02-28 2022-10-04 上海复宏汉霖生物技术股份有限公司 抗cd137构建体、多特异性抗体及其用途
BR112022016491A2 (pt) 2020-02-28 2022-10-11 Shanghai Henlius Biotech Inc Construto anti-cd137 e usos do mesmo
WO2021177980A1 (en) 2020-03-06 2021-09-10 Genentech, Inc. Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
CA3174680A1 (en) 2020-03-13 2021-09-16 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
PE20230259A1 (es) 2020-03-19 2023-02-07 Genentech Inc Anticuerpos anti-tgf-beta con selectividad de isoforma y metodos de uso
US11999787B2 (en) 2020-03-24 2024-06-04 Genentech, Inc. Tie2-binding agents and methods of use
JP2023518841A (ja) 2020-03-26 2023-05-08 ジェネンテック， インコーポレイテッド 宿主細胞タンパク質が減少した修飾哺乳動物細胞
US20240294650A1 (en) 2020-03-31 2024-09-05 Alector Llc Anti-mertk antibodies and methods of use thereof
EP4126934A1 (de) 2020-04-01 2023-02-08 University of Rochester Monoklonale antikörper gegen das hämagglutinin (ha) und die neuraminidase (na) von influenza-h3n2-viren
US12523662B2 (en) 2020-04-02 2026-01-13 Seattle Children's Hospital Antibodies that specifically bind peptides associated with the primary immunodeficiencies: Wiskott-Aldrich syndrome and x-linked agammaglobulinemia
WO2021198511A1 (en) 2020-04-03 2021-10-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of sars-cov-2 infection
EP4127724A1 (de) 2020-04-03 2023-02-08 Genentech, Inc. Therapeutische und diagnostische verfahren für krebs
AU2021247286A1 (en) 2020-04-03 2022-10-20 Alector Llc Methods of use of anti-TREM2 antibodies
CA3179416A1 (en) 2020-04-07 2021-10-14 Albert Einstein College Of Medicine Method of treating and preventing ocular disease with hsv-2 delta gd
WO2021209458A1 (en) 2020-04-14 2021-10-21 Ares Trading S.A. Combination treatment of cancer
CN115485028A (zh) 2020-04-15 2022-12-16 豪夫迈·罗氏有限公司 免疫缀合物
EP4139359A1 (de) 2020-04-24 2023-03-01 Genentech, Inc. Verfahren zur verwendung von anti-cd79b-immunkonjugaten
US12559575B2 (en) 2020-04-27 2026-02-24 The Regents Of The University Of California Isoform-independent antibodies to lipoprotein(a)
KR20230002261A (ko) 2020-04-28 2023-01-05 더 락커펠러 유니버시티 항-sars-cov-2 중화 항체 및 이의 사용 방법
JP2023523450A (ja) 2020-04-28 2023-06-05 ジェネンテック， インコーポレイテッド 非小細胞肺がん免疫療法のための方法及び組成物
JP2023527962A (ja) 2020-05-03 2023-07-03 レヴィーナ （スジョウ） バイオファーマ カンパニー， リミテッド 抗ｔｒｏｐ２抗体を含む抗体薬物複合体（ａｄｃ）、かかるａｄｃを含む組成物、ならびにそれらを作製および使用する方法
WO2021224401A1 (en) 2020-05-07 2021-11-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for determining a reference range of β-galactose exposure platelet
WO2021228917A1 (en) 2020-05-15 2021-11-18 F. Hoffmann-La Roche Ag Prevention of visible particle formation in parenteral protein solutions
JP2023525898A (ja) 2020-05-19 2023-06-19 エフ． ホフマン－ラ ロシュ アーゲー 非経口タンパク質溶液における可視粒子の形成を防止するためのキレート剤の使用
JP2023528375A (ja) 2020-05-29 2023-07-04 ２３アンドミー・インコーポレイテッド 抗ｃｄ２００ｒ１抗体及びその使用方法
BR112022024629A2 (pt) 2020-06-02 2023-02-23 Dynamicure Biotechnology Llc Construtos anti-cd93 e seus usos
CN116529260A (zh) 2020-06-02 2023-08-01 当康生物技术有限责任公司 抗cd93构建体及其用途
JP2023527578A (ja) 2020-06-05 2023-06-29 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 眼疾患を処置するための方法及び医薬組成物
EP4161644A2 (de) 2020-06-08 2023-04-12 F. Hoffmann-La Roche AG Anti-hbv-antikörper und verfahren zur verwendung
WO2021249969A1 (en) 2020-06-10 2021-12-16 Merck Patent Gmbh Combination product for the treatment of cancer diseases
GB202008860D0 (en) 2020-06-11 2020-07-29 Univ Oxford Innovation Ltd BTLA antibodies
EP4165415A1 (de) 2020-06-12 2023-04-19 Genentech, Inc. Verfahren und zusammensetzungen zur krebsimmuntherapie
CA3181820A1 (en) 2020-06-16 2021-12-23 Genentech, Inc. Methods and compositions for treating triple-negative breast cancer
IL298946A (en) 2020-06-18 2023-02-01 Genentech Inc Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
PE20231552A1 (es) 2020-06-19 2023-10-03 Hoffmann La Roche Anticuerpos biespecificos para linfocitos t activados por proteasa
TWI852680B (zh) 2020-06-19 2024-08-11 瑞士商赫孚孟拉羅股份公司 與 cd3 及 cd19 結合之抗體
KR20230025665A (ko) 2020-06-19 2023-02-22 에프. 호프만-라 로슈 아게 Cd3에 결합하는 항체
BR112022025250A2 (pt) 2020-06-19 2022-12-27 Hoffmann La Roche Moléculas, um ou mais polinucleotídeos, um ou mais vetores, célula hospedeira, métodos para produzir uma molécula e induzir a lise de uma célula, composição farmacêutica, uso da molécula, métodos de tratamento de uma doença e invenção
AU2021291005A1 (en) 2020-06-19 2023-01-05 F. Hoffmann-La Roche Ag Antibodies binding to CD3 and FolR1
WO2021255146A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cea
CN116234824A (zh) 2020-06-22 2023-06-06 阿尔米雷尔有限公司 抗il-36抗体及其使用方法
IL297880A (en) 2020-06-23 2023-01-01 Hoffmann La Roche Agonistic cd28 antigen binding molecules targeting her2
US20220041672A1 (en) 2020-06-24 2022-02-10 Genentech, Inc. Apoptosis resistant cell lines
CN115916830A (zh) 2020-06-25 2023-04-04 豪夫迈·罗氏有限公司 抗cd3/抗cd28双特异性抗原结合分子
CA3184618A1 (en) 2020-07-02 2022-01-06 John C. Timmer Polypeptides comprising modified il-2 polypeptides and uses thereof
JP2023532764A (ja) 2020-07-07 2023-07-31 エフ． ホフマン－ラ ロシュ アーゲー 治療用タンパク質製剤の安定剤としての代替界面活性剤
WO2022008597A1 (en) 2020-07-08 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of infectious diseases
MX2023000617A (es) 2020-07-17 2023-02-13 Genentech Inc Anticuerpos anti-notch2 y metodos de uso.
CR20230017A (es) 2020-07-21 2023-02-17 Genentech Inc Inductores químicos de degradación conjugados con anticuerpo de brm y métodos de estos
EP4189395A1 (de) 2020-07-28 2023-06-07 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren und zusammensetzungen zur prävention und behandlung von krebs
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
EP4188550A1 (de) 2020-07-29 2023-06-07 Dynamicure Biotechnology LLC Anti-cd93 konstrukte und deren verwendungen
JP2023536602A (ja) 2020-08-03 2023-08-28 ジェネンテック， インコーポレイテッド リンパ腫のための診断及び治療方法
US20230324408A1 (en) 2020-08-05 2023-10-12 Juno Therapeutics, Inc. Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
CN116648507A (zh) 2020-08-28 2023-08-25 基因泰克公司 宿主细胞蛋白的CRISPR/Cas9多重敲除
EP4208259A2 (de) 2020-09-04 2023-07-12 NovaRock Biotherapeutics, Ltd. Nectin-4-antikörper und verwendungen davon
JP2023541627A (ja) 2020-09-14 2023-10-03 イシュノス サイエンシズ ソシエテ アノニム Ｉｌ１ｒａｐに結合する抗体及びその使用
US20240010750A1 (en) 2020-09-15 2024-01-11 Bayer Aktiengesellschaft Novel anti-a2ap antibodies and uses thereof
EP3970752A1 (de) 2020-09-17 2022-03-23 Merck Patent GmbH Moleküle mit löslichkeitsmarkierung und zugehörige verfahren
WO2022064049A1 (en) 2020-09-28 2022-03-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for diagnosing brucella infection
CA3193569A1 (en) 2020-09-28 2022-03-31 Xiaofeng Liu Anti-sclerostin constructs and uses thereof
IL301547A (en) 2020-10-05 2023-05-01 Genentech Inc Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
AR123855A1 (es) 2020-10-20 2023-01-18 Genentech Inc Anticuerpos anti-mertk conjugados con peg y métodos de uso
WO2022084210A1 (en) 2020-10-20 2022-04-28 F. Hoffmann-La Roche Ag Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors
WO2022084300A1 (en) 2020-10-20 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosis and monitoring form of coronavirus infection
WO2022084531A1 (en) 2020-10-23 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating glioma
WO2022093981A1 (en) 2020-10-28 2022-05-05 Genentech, Inc. Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
WO2022090529A1 (en) 2020-11-02 2022-05-05 Ares Trading S.A. Combination treatment of cancer
WO2022090527A1 (en) 2020-11-02 2022-05-05 Ares Trading S.A. Combination treatment of cancer
CA3196191A1 (en) 2020-11-04 2022-05-12 Chi-Chung Li Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
IL302400A (en) 2020-11-04 2023-06-01 Genentech Inc Subcutaneous dosing of bispecific anti-CD20/anti-CD3 antibodies
CA3196539A1 (en) 2020-11-04 2022-05-12 Chi-Chung Li Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
WO2022098870A1 (en) 2020-11-04 2022-05-12 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies
WO2022101481A1 (en) 2020-11-16 2022-05-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating uveal melanoma
AU2021376837A1 (en) 2020-11-16 2023-06-15 F. Hoffmann-La Roche Ag Fab high mannose glycoforms
WO2022120352A1 (en) 2020-12-02 2022-06-09 Alector Llc Methods of use of anti-sortilin antibodies
JP2023553861A (ja) 2020-12-02 2023-12-26 上海復宏漢霖生物技術股▲フン▼有限公司 抗ＧＡＲＰ／ＴＧＦβ抗体及び使用方法
CN116635403A (zh) 2020-12-04 2023-08-22 豪夫迈·罗氏有限公司 pH依赖性突变型白细胞介素-2多肽
AU2021401934A1 (en) 2020-12-14 2023-06-22 Allogene Therapeutics, Inc. Methods and reagents for characterizing car t cells for therapies
EP4263609A1 (de) 2020-12-17 2023-10-25 F. Hoffmann-La Roche AG Anti-hla-g-antikörper und verwendung davon
WO2022140797A1 (en) 2020-12-23 2022-06-30 Immunowake Inc. Immunocytokines and uses thereof
WO2022148853A1 (en) 2021-01-11 2022-07-14 F. Hoffmann-La Roche Ag Immunoconjugates
EP4277926A1 (de) 2021-01-15 2023-11-22 The Rockefeller University Neutralisierende anti-sars-cov-2-antikörper
TW202245811A (zh) 2021-02-03 2022-12-01 美商異基因治療有限公司 用於ｃａｒ ｔ細胞藥物產品的調配物與製程
CA3208641A1 (en) 2021-02-19 2022-08-25 Ashraf AMANULLAH Formulations of dr5 binding polypeptides
US20240317847A1 (en) 2021-02-26 2024-09-26 Bayer Aktiengesellschaft INHIBITORS OF IL-11 OR IL-11Ra FOR USE IN THE TREATMENT OF ABNORMAL UTERINE BLEEDING
EP4301467A1 (de) 2021-03-01 2024-01-10 Xilio Development, Inc. Kombination von ctla4 und pd1/pdl1-antikörpern zur behandlung von krebs
TW202246324A (zh) 2021-03-01 2022-12-01 美商艾希利歐發展股份有限公司 用於治療癌症的經掩蔽之ｃｔｌａ４及ｐｄ１／ｐｄｌ１抗體之組合
WO2022184853A1 (en) 2021-03-03 2022-09-09 Pierre Fabre Medicament Anti-vsig4 antibody or antigen binding fragment and uses thereof
CN117440832A (zh) 2021-03-03 2024-01-23 索伦托药业有限公司 包括抗bcma抗体的抗体-药物缀合物
WO2022187863A1 (en) 2021-03-05 2022-09-09 Dynamicure Biotechnology Llc Anti-vista constructs and uses thereof
WO2022189377A1 (en) 2021-03-09 2022-09-15 F. Hoffmann-La Roche Ag Combination therapy of pd-1-targeted il-2 variant immunoconjugates and fap/4-1bb binding molecules
EP4304724A1 (de) 2021-03-09 2024-01-17 F. Hoffmann-La Roche AG Kombinationstherapie aus pd-1-gerichtetem il-2-varianten-immunkonjugat und bispezifischen anti-tyrp1/anti-cd3-antikörpern
WO2022192898A2 (en) 2021-03-10 2022-09-15 Immunowake Inc. Immunomodulatory molecules and uses thereof
JP2024512377A (ja) 2021-03-12 2024-03-19 ジェネンテック， インコーポレイテッド 抗ｋｌｋ７抗体、抗ｋｌｋ５抗体、多重特異性抗ｋｌｋ５／ｋｌｋ７抗体、及び使用方法
IL305283A (en) 2021-03-15 2023-10-01 Genentech Inc Compositions and methods for the treatment of lupus nephritis
US20240165094A1 (en) 2021-03-17 2024-05-23 Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating melanoma
JP2024512002A (ja) 2021-03-18 2024-03-18 アレクトル エルエルシー 抗ｔｍｅｍ１０６ｂ抗体、及び、その使用方法
WO2022197877A1 (en) 2021-03-19 2022-09-22 Genentech, Inc. Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
AU2022244229A1 (en) 2021-03-22 2023-09-14 Juno Therapeutics, Inc. Method to assess potency of viral vector particles
CA3210581A1 (en) 2021-03-22 2022-09-29 Neil HAIG Methods of determining potency of a therapeutic cell composition
JP2024511610A (ja) 2021-03-23 2024-03-14 アレクトル エルエルシー コロナウイルス感染の治療及び予防のための抗ｔｍｅｍ１０６ｂ抗体
TW202300648A (zh) 2021-03-25 2023-01-01 美商當康生物科技有限公司 抗-igfbp7構築體及其用途
CA3215274A1 (en) 2021-03-30 2022-10-06 Bayer Aktiengesellschaft Anti-sema3a antibodies and uses thereof
CN117157312A (zh) 2021-03-30 2023-12-01 豪夫迈·罗氏有限公司 蛋白酶活化的多肽
US20240239895A1 (en) 2021-04-09 2024-07-18 Genentech, Inc. Combination therapy with a raf inhibitor and a pd-1 axis inhibitor
AR125344A1 (es) 2021-04-15 2023-07-05 Chugai Pharmaceutical Co Ltd Anticuerpo anti-c1s
WO2022225880A1 (en) 2021-04-19 2022-10-27 Genentech, Inc. Modified mammalian cells
WO2022223791A1 (en) 2021-04-23 2022-10-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cell senescence accumulation related disease
AU2021443318A1 (en) 2021-04-30 2023-09-07 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
WO2022229469A1 (en) 2021-04-30 2022-11-03 Pierre Fabre Medicament New stable anti-vista antibody
EP4329800A1 (de) 2021-04-30 2024-03-06 F. Hoffmann-La Roche AG Dosierung zur behandlung mit bispezifischem anti-cd20/anti-cd3-antikörper
WO2022233718A2 (en) 2021-05-03 2022-11-10 Merck Patent Gmbh Her2 targeting fc antigen binding fragment-drug conjugates
EP4334343A2 (de) 2021-05-06 2024-03-13 The Rockefeller University Neutralisierende anti-sars-cov-2-antikörper und verfahren zur verwendung davon
CA3218170A1 (en) 2021-05-12 2022-11-17 Jamie Harue HIRATA Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
JP2024518545A (ja) 2021-05-14 2024-05-01 ジェネンテック， インコーポレイテッド Ｔｒｅｍ２のアゴニスト
CA3219124A1 (en) 2021-05-18 2022-11-24 University Of Tennessee Research Foundation Antibody-peptide fusion proteins for treating amyloid disorders
KR20240010469A (ko) 2021-05-21 2024-01-23 제넨테크, 인크. 관심 재조합 생성물의 생성을 위한 변형된 세포
US20240226319A1 (en) 2021-05-25 2024-07-11 Merck Patent Gmbh Egfr targeting fc antigen binding fragment-drug conjugates
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
WO2022255440A1 (en) 2021-06-04 2022-12-08 Chugai Seiyaku Kabushiki Kaisha Anti-ddr2 antibodies and uses thereof
CA3220380A1 (en) 2021-06-07 2022-12-15 Rinat ZAYNAGETDINOV Combination treatment of cancer
CA3216220A1 (en) 2021-06-09 2022-12-15 F. Hoffmann-La Roche Ag Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
WO2022265912A1 (en) 2021-06-16 2022-12-22 Gundersen Lutheran Medical Foundation, Inc. Antibodies targeting an amphiregulin-derived cell surface neo-epitope
WO2022266223A1 (en) 2021-06-16 2022-12-22 Alector Llc Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
WO2022266221A1 (en) 2021-06-16 2022-12-22 Alector Llc Monovalent anti-mertk antibodies and methods of use thereof
US12227574B2 (en) 2021-06-17 2025-02-18 Amberstone Biosciences, Inc. Anti-CD3 constructs and uses thereof
CA3222880A1 (en) 2021-06-18 2022-12-22 Jeffrey Stavenhagen Antibodies which bind human fibrin or fibrinogen ?c domain and methods of use
CN117616123B (zh) 2021-06-25 2024-11-08 中外制药株式会社 抗ctla-4抗体
CN117545779B (zh) 2021-06-25 2025-04-04 中外制药株式会社 抗ctla-4抗体的用途
KR20240029062A (ko) 2021-07-02 2024-03-05 메르크 파텐트 게엠베하 항-protac 항체 및 복합체
CA3224853A1 (en) 2021-07-14 2023-01-19 Gautham GAMPA Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
TW202309102A (zh) 2021-07-20 2023-03-01 美商英伊布里克斯公司 靶向cd8之經修飾il-2多肽及其用途
EP4373854A1 (de) 2021-07-20 2024-05-29 Inhibrx, Inc. Cd8-bindende polypeptide und verwendungen davon
WO2023004386A1 (en) 2021-07-22 2023-01-26 Genentech, Inc. Brain targeting compositions and methods of use thereof
AU2022315528A1 (en) 2021-07-22 2023-10-19 F. Hoffmann-La Roche Ag Heterodimeric fc domain antibodies
CA3227537A1 (en) 2021-07-27 2023-02-02 Morphosys Ag Combinations of antigen binding molecules
US20240279336A1 (en) 2021-07-30 2024-08-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Chimeric proteins and methods of immunotherapy
WO2023012147A1 (en) 2021-08-03 2023-02-09 F. Hoffmann-La Roche Ag Bispecific antibodies and methods of use
EP4384553A1 (de) 2021-08-13 2024-06-19 Genentech, Inc. Dosierung für antitryptase-antikörper
CN117858905A (zh) 2021-08-19 2024-04-09 豪夫迈·罗氏有限公司 多价抗变体fc区抗体及使用方法
MX2024002295A (es) 2021-08-27 2024-03-07 Genentech Inc Metodos para tratar las patologias de tau.
JP2024534853A (ja) 2021-08-30 2024-09-26 ジェネンテック， インコーポレイテッド 抗ポリビキチン多重特異性抗体
US20240368280A1 (en) 2021-09-02 2024-11-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Anti-cecam6 antibodies with reduced side-effects
CN118541392A (zh) 2021-09-28 2024-08-23 准星生物医药有限公司 多种形式的分子复合物
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2023058723A1 (ja) 2021-10-08 2023-04-13 中外製薬株式会社 プレフィルドシリンジ製剤の調製方法
JP2024537335A (ja) 2021-10-14 2024-10-10 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規インターロイキン－７イムノコンジュゲート
WO2023062048A1 (en) 2021-10-14 2023-04-20 F. Hoffmann-La Roche Ag Alternative pd1-il7v immunoconjugates for the treatment of cancer
WO2023069919A1 (en) 2021-10-19 2023-04-27 Alector Llc Anti-cd300lb antibodies and methods of use thereof
US20240426823A1 (en) 2021-11-03 2024-12-26 Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating triple negative breast cancer (tnbc)
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy
WO2023086807A1 (en) 2021-11-10 2023-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
IL312692A (en) 2021-11-16 2024-07-01 Genentech Inc Methods and compositions for the treatment of systemic lupus erythematosus (SLE) with musontuzumab
EP4437006A1 (de) 2021-11-26 2024-10-02 F. Hoffmann-La Roche AG Kombinationstherapie von bispezifischen anti-tyrp1/anti-cd3-antikörpern und tyrp1-spezifischen antikörpern
JP7367262B1 (ja) 2021-12-01 2023-10-23 中外製薬株式会社 抗体含有製剤の調製方法
AR127887A1 (es) 2021-12-10 2024-03-06 Hoffmann La Roche Anticuerpos que se unen a cd3 y plap
CA3240585A1 (en) 2021-12-17 2023-06-22 Wenfeng Xu Anti-ox40 antibodies, multispecific antibodies and methods of use
EP4448579A4 (de) 2021-12-17 2026-02-18 Shanghai Henlius Biotech Inc Anti-ox40-antikörper und verfahren zur verwendung
US20250041261A1 (en) 2021-12-21 2025-02-06 Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating melanoma
EP4454662A4 (de) 2021-12-23 2025-04-23 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-dll3-antikörper und pharmazeutische verwendung davon sowie antikörper-wirkstoff-konjugat mit anti-dll3-antikörper
WO2023133394A1 (en) 2022-01-05 2023-07-13 Inhibrx, Inc. Gamma delta t-cell-binding polypeptides and uses thereof
US20250109203A1 (en) 2022-01-05 2025-04-03 Inhibrx Biosciences, Inc. Gamma Delta T-Cell-Targeted Modified IL-2 Polypeptides and Uses Thereof
WO2023141445A1 (en) 2022-01-19 2023-07-27 Genentech, Inc. Anti-notch2 antibodies and conjugates and methods of use
AR128331A1 (es) 2022-01-26 2024-04-17 Genentech Inc Inductores químicos de degradación conjugados con anticuerpos y métodos de estos
AR128330A1 (es) 2022-01-26 2024-04-17 Genentech Inc Inductores químicos de degradación conjugados con anticuerpo y métodos de estos
WO2023144973A1 (ja) 2022-01-27 2023-08-03 中外製薬株式会社 抗ｖｅｇｆ抗体及びパクリタキセルと組み合わせて使用する抗ｐｄ－ｌ１抗体を含む医薬組成物
WO2023144235A1 (en) 2022-01-27 2023-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for monitoring and treating warburg effect in patients with pi3k-related disorders
WO2023147399A1 (en) 2022-01-27 2023-08-03 The Rockefeller University Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
CN118765204A (zh) 2022-02-23 2024-10-11 艾利妥 抗trem2抗体的使用方法
WO2024026472A2 (en) 2022-07-29 2024-02-01 Alector Llc Transferrin receptor antigen-binding domains and uses therefor
US20250205350A1 (en) 2022-03-10 2025-06-26 Vivasor, Inc. Antibody-Drug Conjugates and Uses Thereof
IL314828A (en) 2022-03-11 2024-10-01 Mablink Bioscience Antibody-drug conjugates and their uses
MX2024011468A (es) 2022-03-23 2024-09-25 Hoffmann La Roche Tratamiento conjunto de un anticuerpo biespecifico anti-cd20/anti-cd3 y quimioterapia.
EP4499708A1 (de) 2022-03-25 2025-02-05 Shanghai Henlius Biotech, Inc. Anti-msln-antikörper und verfahren zur verwendung
AR128876A1 (es) 2022-03-28 2024-06-19 Hoffmann La Roche Anticuerpos biespecíficos de linfocitos t activables con proteasa folr1 mejorados
KR20240169042A (ko) 2022-04-01 2024-12-02 제넨테크, 인크. 항-fcrh5/항-cd3 이중특이성 항체로 치료하기 위한 투약법
CN116925223A (zh) 2022-04-02 2023-10-24 普米斯生物技术(珠海)有限公司 抗pd-1单克隆抗体及其衍生物和用途
US20250215101A1 (en) 2022-04-08 2025-07-03 Inhibrx Biosciences, Inc. DR5 Agonist and PLK1 Inhibitor or CDK Inhibitor Combination Therapy
AU2023251832A1 (en) 2022-04-13 2024-10-17 F. Hoffmann-La Roche Ag Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
AR129062A1 (es) 2022-04-13 2024-07-10 Genentech Inc Composiciones farmacéuticas de proteínas terapéuticas y métodos de uso
WO2023210670A1 (ja) 2022-04-26 2023-11-02 中外製薬株式会社 医薬製剤含有フィルター内蔵シリンジ
EP4515231A1 (de) 2022-04-28 2025-03-05 Allogene Therapeutics, Inc. Verfahren zur spenderzellenanalyse
EP4514470A1 (de) 2022-04-29 2025-03-05 Broadwing Bio LLC Angiopoietin-verwandte protein-7-spezifische antikörper und verwendungen davon
EP4514389A1 (de) 2022-04-29 2025-03-05 Purinomia Biotech, Inc. Verfahren und zusammensetzungen zur behandlung von eosinophil-bedingten erkrankungen und störungen
AU2023260823A1 (en) 2022-04-29 2024-11-14 Broadwing Bio Llc Bispecific antibodies and methods of treating ocular disease
AU2023260822A1 (en) 2022-04-29 2024-11-14 Broadwing Bio Llc Complement factor h related 4-specific antibodies and uses thereof
WO2023213814A1 (en) 2022-05-02 2023-11-09 Pierre Fabre Medicament New formulation of anti vista antibody
CA3257258A1 (en) 2022-05-03 2023-11-09 Genentech, Inc. Anti-Ly6E antibodies, immunoconjugates, and their uses
US20250277018A1 (en) 2022-05-05 2025-09-04 Inhibrx Biosciences, Inc. Albumin-Binding Polypeptides and Uses Thereof
AU2022458320A1 (en) 2022-05-11 2024-11-28 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023230432A1 (en) 2022-05-23 2023-11-30 Inhibrx, Inc. Dr5 agonist and iap antagonist combination therapy
WO2023235699A1 (en) 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof
WO2023235415A1 (en) 2022-06-01 2023-12-07 Genentech, Inc. Method to identify a patient with an increased likelihood of chemotherapy-induced peripheral neuropathy
IL317449A (en) 2022-06-07 2025-02-01 Genentech Inc Method for determining the efficacy of a lung cancer treatment comprising an anti-PD-L1 antagonist and an anti-TIGIT antibody-antagonist
WO2023239803A1 (en) 2022-06-08 2023-12-14 Angiex, Inc. Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
WO2023240218A1 (en) 2022-06-09 2023-12-14 Allogene Therapeutics Inc. Methods for detecting genomic abnormalities in cells
US20250325636A1 (en) 2022-06-09 2025-10-23 Institut National de la Santé et de la Recherche Médicale Use of endothelin receptor type b agonists for the treatment of aortic valve stenosis
AU2023283838A1 (en) 2022-06-11 2025-01-23 Inhibrx Biosciences, Inc. Fcrn-binding polypeptides and uses thereof
EP4536358A1 (de) 2022-06-13 2025-04-16 Genentech Inc. Verfahren zur verzögerung oder prävention des auftretens von morbus alzheimer mit crenezumab
WO2024008799A1 (en) 2022-07-06 2024-01-11 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of proliferative glomerulonephritis
WO2024013234A1 (en) 2022-07-13 2024-01-18 Institut National de la Santé et de la Recherche Médicale Methods for diagnosis, prognosis, stratification and treating of myocarditis
EP4554978A1 (de) 2022-07-13 2025-05-21 Genentech, Inc. Dosierung zur behandlung mit bispezifischen anti-fcrh5/anti-cd3-antikörpern
IL318252A (en) 2022-07-19 2025-03-01 Genentech Inc Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies
CN120865421A (zh) 2022-07-22 2025-10-31 百时美施贵宝公司 结合至人类pad4的抗体及其用途
CR20250056A (es) 2022-07-22 2025-03-19 Genentech Inc Moléculas de unión al antígeno anti-steap1 y sus usos.
EP4561703A1 (de) 2022-07-29 2025-06-04 Alector LLC Anti-gpnmb-antikörper und verfahren zur verwendung davon
WO2024026471A1 (en) 2022-07-29 2024-02-01 Alector Llc Cd98hc antigen-binding domains and uses therefor
US20260060969A1 (en) 2022-08-04 2026-03-05 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of lymphoproliferative disorders
WO2024033400A1 (en) 2022-08-10 2024-02-15 Institut National de la Santé et de la Recherche Médicale Sk2 inhibitor for the treatment of pancreatic cancer
EP4568670A1 (de) 2022-08-10 2025-06-18 Institut National de la Santé et de la Recherche Médicale Sigmar1-ligand zur behandlung von bauchspeicheldrüsenkrebs
WO2024040090A1 (en) 2022-08-16 2024-02-22 Allogene Therapeutics Inc. In vitro method for inhibiting hhv-6 infection
TW202417476A (zh) 2022-08-18 2024-05-01 英商英美偌科有限公司 Ｔ細胞受體及其融合蛋白
WO2024049949A1 (en) 2022-09-01 2024-03-07 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
US20260078185A1 (en) 2022-09-07 2026-03-19 Dynamicure Biotechnology Llc Anti-vista constructs and uses thereof
TW202413414A (zh) 2022-09-08 2024-04-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ｉｌｔ４抗體及其醫藥用途
WO2024068572A1 (en) 2022-09-28 2024-04-04 F. Hoffmann-La Roche Ag Improved protease-activatable t cell bispecific antibodies
JP2025534285A (ja) 2022-09-29 2025-10-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト プロテアーゼ活性化ポリペプチド
WO2024077239A1 (en) 2022-10-07 2024-04-11 Genentech, Inc. Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
WO2024086796A1 (en) 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies
WO2024084034A1 (en) 2022-10-21 2024-04-25 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of osteoarthritis
TW202426505A (zh) 2022-10-25 2024-07-01 美商建南德克公司 癌症之治療及診斷方法
KR20250099702A (ko) 2022-11-04 2025-07-02 길리애드 사이언시즈, 인코포레이티드 항-ccr8 항체, 화학요법 및 면역요법 조합을 사용하는 항암 요법
AU2023375342A1 (en) 2022-11-08 2025-04-24 F. Hoffmann-La Roche Ag Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
WO2024100170A1 (en) 2022-11-11 2024-05-16 F. Hoffmann-La Roche Ag Antibodies binding to hla-a*02/foxp3
EP4619045A1 (de) 2022-11-17 2025-09-24 Sanofi Ceacam5-antikörper-wirkstoff-konjugate und verfahren zur verwendung davon
TW202440623A (zh) 2022-11-28 2024-10-16 美商艾洛基因醫療公司 靶向密連蛋白１８﹒２之嵌合抗原受體及結合劑以及其用途
CN119546630A (zh) 2022-12-08 2025-02-28 南京诺唯赞生物科技股份有限公司 特异性结合rsv的抗体
WO2024121380A1 (en) 2022-12-08 2024-06-13 Pierre Fabre Medicament Vaccinal composition and adjuvant
CN120693406A (zh) 2022-12-12 2025-09-23 基因泰克公司 优化多肽唾液酸含量
AU2023408612A1 (en) 2022-12-20 2025-07-03 BioNTech SE Methods of treating pancreatic cancer with a pd-1 axis binding antagonist and an rna vaccine
WO2024133723A1 (en) 2022-12-22 2024-06-27 Institut National de la Santé et de la Recherche Médicale Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy
JP2026503962A (ja) 2022-12-27 2026-02-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｐｒｏｔａｃ抗体および複合体
WO2024145398A1 (en) 2022-12-27 2024-07-04 Yale University Antibody drug conjugates
KR20250167678A (ko) 2022-12-30 2025-12-01 레메젠 (상하이) 씨오., 엘티디. 이중특이적 항체 및 이의 응용
WO2024148232A2 (en) 2023-01-06 2024-07-11 Alector Llc Anti-il18 binding protein antibodies and methods of use thereof
IL321951A (en) 2023-01-18 2025-09-01 Genentech Inc Multispecific antibodies and their uses
AU2024209384A1 (en) 2023-01-20 2025-06-26 F. Hoffmann-La Roche Ag Recombinant fc domain - il2 variant polypeptides and combination therapy with membrane-anchored antigen binding polypeptides
EP4655007A1 (de) 2023-01-23 2025-12-03 Yale University Antikörper-oligonukleotid-konjugate
JP2026505747A (ja) 2023-01-25 2026-02-18 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｃｓｆ１ｒおよびｃｄ３に結合する抗体
KR20250153805A (ko) 2023-02-27 2025-10-27 쑤저우 선카디아 바이오파마수티컬즈 컴퍼니 리미티드 항-dll3 항체, 이의 항체-약물 접합체 및 이의 의약적 용도
WO2024191785A1 (en) 2023-03-10 2024-09-19 Genentech, Inc. Fusions with proteases and uses thereof
AU2024234589A1 (en) 2023-03-16 2025-08-28 Itabmed Co., Ltd. Multispecific antigen binding proteins and uses thereof
WO2024197302A1 (en) 2023-03-23 2024-09-26 Yale University Compositions and methods for delivering antibody oligonucleotide conjugates for exon skipping
WO2024206738A1 (en) 2023-03-31 2024-10-03 Immunai Inc. Humanized anti-trem2 antibodies
WO2024206788A1 (en) 2023-03-31 2024-10-03 Genentech, Inc. Anti-alpha v beta 8 integrin antibodies and methods of use
WO2024211235A1 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024211234A1 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
EP4687997A2 (de) 2023-04-05 2026-02-11 Sorrento Therapeutics, Inc. Antikörper-wirkstoff-konjugate und verwendungen davon
EP4696711A1 (de) 2023-04-13 2026-02-18 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antigenbindendes molekül mit spezifischer bindung an egfr und muc1, wirkstoffkonjugat davon und medizinische verwendung davon
EP4696321A1 (de) 2023-04-14 2026-02-18 Chugai Seiyaku Kabushiki Kaisha Verfahren zur stabilisierung einer proteinhaltigen pharmazeutischen zubereitung
EP4695287A1 (de) 2023-04-14 2026-02-18 Twist Bioscience Corporation Zusammensetzungen und verfahren im zusammenhang mit dkk1-bindemitteln
CN121263210A (zh) 2023-04-17 2026-01-02 沛科生物公司 抗体和抗体-药物偶联物以及使用方法和合成工艺及中间体
CN121311765A (zh) 2023-04-18 2026-01-09 朱诺治疗学股份有限公司 评估治疗性细胞组合物的效力的细胞毒性测定
WO2024227154A1 (en) 2023-04-28 2024-10-31 Broadwing Bio Llc Complement component 3 (c3)-specific antibodies and uses thereof
TW202448949A (zh) 2023-05-05 2024-12-16 美商建南德克公司 用抗ｆｃｒｈ５／抗ｃｄ３雙特異性抗體進行治療之給藥
AU2024269754A1 (en) 2023-05-08 2025-10-23 F. Hoffmann-La Roche Ag Targeted interferon alpha fusion proteins and methods of use
IL324490A (en) 2023-05-10 2026-01-01 Genentech Inc Methods and preparations for treating cancer
TW202509065A (zh) 2023-05-16 2025-03-01 瑞士商赫孚孟拉羅股份公司 經ｐｄ－１調節之ｉｌ－２免疫結合物及其用途
WO2024240162A1 (en) 2023-05-23 2024-11-28 Shanghai Allygen Biologics Co., Ltd. Pd-l1 and trop-2 targeting conjugates comprising effector molecules and uses thereof
WO2024245951A1 (en) 2023-05-26 2024-12-05 Institut National de la Santé et de la Recherche Médicale Combination of slc8a1 inhibitor and mitochondria-targeted antioxidant for treating melanoma
WO2024248867A1 (en) 2023-05-31 2024-12-05 Genentech, Inc. Methods of treating tgf beta-related disorders with anti-transforming growth factor beta 3 antibodies
CN121241068A (zh) 2023-06-01 2025-12-30 豪夫迈·罗氏有限公司 靶向bcma和cd28的双特异性抗体
AR132805A1 (es) 2023-06-01 2025-07-30 Hoffmann La Roche Moléculas de unión al antígeno inmunoestimuladoras que se unen específicamente a bcma
WO2024251255A1 (zh) 2023-06-08 2024-12-12 江苏恒瑞医药股份有限公司 抗npr1抗体及其医药用途
WO2024254455A1 (en) 2023-06-08 2024-12-12 Genentech, Inc. Macrophage signatures for diagnostic and therapeutic methods for lymphoma
EP4477236A1 (de) 2023-06-14 2024-12-18 Inatherys Kombinationstherapie zur behandlung eines tumors mit adc mit anti-cd71-antikörpern und bh3-mimetika
WO2024256635A1 (en) 2023-06-15 2024-12-19 Institut National de la Santé et de la Recherche Médicale Dpm1 inhibitor for treating cancer
CN121532650A (zh) 2023-06-20 2026-02-13 艾洛基治疗公司 工程化的细胞的检测方法
WO2024261302A1 (en) 2023-06-22 2024-12-26 Institut National de la Santé et de la Recherche Médicale Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
WO2024263761A1 (en) 2023-06-22 2024-12-26 Genentech, Inc. Antibodies and uses thereof
TW202504929A (zh) 2023-06-22 2025-02-01 美商建南德克公司 用於癌症治療之方法及組成物
WO2025003511A1 (en) 2023-06-30 2025-01-02 Morphosys Ag Dual-targeting of flt3 and cd123 co-expressing tumor cells by functional complementation of cycat® halfbody molecules
WO2025024265A1 (en) 2023-07-21 2025-01-30 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad4 modulators
WO2025021928A1 (en) 2023-07-25 2025-01-30 Merck Patent Gmbh Iduronidase-cleavable compounds
WO2025021838A1 (en) 2023-07-26 2025-01-30 F. Hoffmann-La Roche Ag Antibodies binding to cd3
WO2025034806A1 (en) 2023-08-08 2025-02-13 Wisconsin Alumni Research Foundation Single-domain antibodies and variants thereof against fibroblast activation protein
CN121666400A (zh) 2023-08-09 2026-03-13 豪夫迈·罗氏有限公司 单特异性和多特异性抗trem2抗体、其方法和用途
WO2025032069A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
CN121712801A (zh) 2023-08-14 2026-03-20 莫佛塞斯有限责任公司 包含空间位阻部分的CyCAT半体分子
WO2025038668A1 (en) 2023-08-14 2025-02-20 Voro Therapeutics, Inc. Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof
AU2024324501A1 (en) 2023-08-16 2026-03-05 University Of Tennessee Research Foundation Methods of inhibiting fibril growth
WO2025049345A1 (en) 2023-08-25 2025-03-06 Proteologix Us Inc. Anti-il-13 multispecific antibody constructs and uses thereof
TW202523697A (zh) 2023-08-25 2025-06-16 美商普羅特歐拉吉克適美國公司 抗ｔｓｌｐ抗體構築體及其用途
WO2025048887A1 (en) 2023-09-01 2025-03-06 Inhibrx Biosciences, Inc. Ox40 agonist therapy
WO2025048860A1 (en) 2023-09-01 2025-03-06 Inhibrx Biosciences, Inc. Ox40 agonist therapy
WO2025049905A1 (en) 2023-09-01 2025-03-06 Gennao Bio, Inc. Dnase co-expression in host cells
WO2025045251A2 (en) 2023-09-03 2025-03-06 Kira Pharmaceuticals (Us) Llc Multispecific constructs comprising anti-factor d moiety
WO2025054500A2 (en) 2023-09-08 2025-03-13 Mlab Biosciences, Inc. Bifunctional proteins and uses thereof
AR133909A1 (es) 2023-09-25 2025-11-12 Hoffmann La Roche ANTICUERPO QUE SE UNE A C3bBb
US12122842B1 (en) 2023-09-27 2024-10-22 R&D Systems, Inc. Human CD30-specific binding proteins and uses thereof
WO2025078632A1 (en) 2023-10-12 2025-04-17 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from cancer
WO2025082777A1 (en) 2023-10-17 2025-04-24 Morphosys Ag Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules
WO2025085489A1 (en) 2023-10-17 2025-04-24 Bristol-Myers Squibb Company Gspt1-degrading compounds, anti-cd33 antibodies and antibody-drug conjugates and uses thereof
WO2025087681A1 (en) 2023-10-26 2025-05-01 Morphosys Ag Bispecific antibodies against cd3 and cd20
WO2025106474A1 (en) 2023-11-14 2025-05-22 Genentech, Inc. Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
TW202523328A (zh) 2023-11-17 2025-06-16 美商建南德克公司 Ｍｃｌ－１抑制劑化合物及在抗體藥物結合物中之用途
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途
WO2025117848A1 (en) 2023-12-01 2025-06-05 Genentech, Inc. Low-viscosity variants of antibodies
WO2025129010A1 (en) 2023-12-14 2025-06-19 Genentech, Inc. Methods of structure determination using antibodies
WO2025132479A1 (en) 2023-12-18 2025-06-26 Institut National de la Santé et de la Recherche Médicale Flt3 inhibitor for modulating macrophages polarization
US20260071002A1 (en) 2023-12-20 2026-03-12 Hoffmann-La Roche Inc. Antibodies binding to ceacam5
WO2025137086A1 (en) 2023-12-20 2025-06-26 Genentech, Inc. Reducing alpha-gal
WO2025133042A2 (en) 2023-12-22 2025-06-26 F. Hoffmann-La Roche Ag Activatable fusion proteins and methods of use
WO2025155607A1 (en) 2024-01-16 2025-07-24 Genentech, Inc. Methods of treating urothelial carcinoma with a pd-1 axis binding antagonist and an rna vaccine
WO2025155602A1 (en) 2024-01-16 2025-07-24 Genentech, Inc. Method of treating hemophilia a
WO2025153608A1 (en) 2024-01-18 2025-07-24 Institut National de la Santé et de la Recherche Médicale Wip1 inhibitor for the treatment of glomerular disease
WO2025166077A1 (en) 2024-01-31 2025-08-07 Alector Llc Compositions comprising progranulin and uses thereof
WO2025166045A1 (en) 2024-01-31 2025-08-07 Alector Llc β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF
WO2025166040A1 (en) 2024-01-31 2025-08-07 Alector Llc Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof
WO2025166042A1 (en) 2024-01-31 2025-08-07 Alector Llc Cd98hc antigen-binding domains and uses therefor
WO2025174974A1 (en) 2024-02-14 2025-08-21 Bristol-Myers Squibb Company Anti-cd33 antibodies and uses thereof
WO2025176614A1 (en) 2024-02-20 2025-08-28 F. Hoffmann-La Roche Ag Novel pre-targeting antibodies and uses thereof
WO2025178959A1 (en) 2024-02-20 2025-08-28 University Of Georgia Research Foundation, Inc. Single-domain antibodies and variants thereof against tab1
WO2025181189A1 (en) 2024-03-01 2025-09-04 F. Hoffmann-La Roche Ag Antibodies binding to cd3
WO2025196639A1 (en) 2024-03-21 2025-09-25 Seagen Inc. Cd25 antibodies, antibody-drug conjugates, and uses thereof
WO2025202147A1 (en) 2024-03-27 2025-10-02 F. Hoffmann-La Roche Ag Interleukin-7 immunoconjugates
WO2025210123A1 (en) 2024-04-03 2025-10-09 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for treating cancers
WO2025215060A1 (en) 2024-04-11 2025-10-16 F. Hoffmann-La Roche Ag Antibodies that specifically bind modified oligonucleotides
WO2025226834A1 (en) 2024-04-23 2025-10-30 Attovia Therapeutics, Inc. Il31-binding polypeptides and uses thereof
WO2025226808A1 (en) 2024-04-24 2025-10-30 Genentech, Inc. Compositions and methods of treating lupus nephritis
EP4643858A1 (de) 2024-04-29 2025-11-05 Institut National de la Santé et de la Recherche Médicale Verfahren und pharmazeutische zusammensetzung zur behandlung von gebärmuttererkrankungen
WO2025228998A1 (en) 2024-04-30 2025-11-06 Institut National de la Santé et de la Recherche Médicale Use of hdac4 inhibitors for the treatment of melanoma
WO2025233304A1 (en) 2024-05-08 2025-11-13 F. Hoffmann-La Roche Ag Recombinant fc domain – il7 variant polypeptides and combination therapy with membrane-anchored antigen binding polypeptides
WO2025247829A1 (en) 2024-05-27 2025-12-04 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for treating prostate cancer
WO2025248500A1 (en) 2024-05-31 2025-12-04 Janssen Biotech, Inc. Antibody drug conjugates that target enpp3
WO2025248102A1 (en) 2024-05-31 2025-12-04 Institut National de la Santé et de la Recherche Médicale Tbk1 inhibitor for use in the treatment of vitiligo
WO2025255405A1 (en) 2024-06-06 2025-12-11 Bristol-Myers Squibb Company Anti-fap antibodies and uses thereof
US20250376536A1 (en) 2024-06-06 2025-12-11 Bristol-Myers Squibb Company Multispecific anti-cd40 / anti-fap antibodies and uses thereof
WO2025257151A1 (en) 2024-06-10 2025-12-18 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for treating ciliopathies
US20260056209A1 (en) 2024-06-14 2026-02-26 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof
WO2025264572A1 (en) 2024-06-17 2025-12-26 Alector Llc Transferrin receptor antigen-binding domains and uses therefor
WO2026006162A2 (en) 2024-06-24 2026-01-02 Genentech, Inc. B vitamin modulation
WO2026012976A1 (en) 2024-07-08 2026-01-15 Institut National de la Santé et de la Recherche Médicale Use of inhibitor of gasdermind for treatment of rac2 monogenic disorders
WO2026013071A1 (en) 2024-07-09 2026-01-15 Institut National de la Santé et de la Recherche Médicale Setdb1 inhibitor for use in the treatment of uveal melanoma
WO2026020031A2 (en) 2024-07-18 2026-01-22 Novarock Biotherapeutics, Ltd. Cdh17 antibodies and uses thereof
WO2026030464A1 (en) 2024-07-30 2026-02-05 Genentech, Inc. Dosage regimen for reducing cytokine release syndrome (crs) with anti-fcrh5/anti-cd3 bispecific antibodies in multiple myeloma therapy
WO2026041568A1 (en) 2024-08-20 2026-02-26 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and dotam
WO2026055143A2 (en) 2024-09-03 2026-03-12 Attovia Therapeutics, Inc. Il13-binding polypeptides and uses thereof
WO2026055142A1 (en) 2024-09-03 2026-03-12 Attovia Therapeutics, Inc. Il13 and il31 bispecific polypeptides and uses thereof
WO2026055521A1 (en) 2024-09-06 2026-03-12 University Of Tennessee Research Foundation Antibody-peptide fusion proteins for treating amyloid disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody

Also Published As

Publication number Publication date
EP1034298B1 (de) 2011-11-02
ES2375931T3 (es) 2012-03-07
AU760562B2 (en) 2003-05-15
EP1034298A4 (de) 2005-01-19
PT1034298E (pt) 2012-02-03
EP1034298A1 (de) 2000-09-13
CA2312208A1 (en) 1999-06-17
JP2001526044A (ja) 2001-12-18
WO1999029888A1 (en) 1999-06-17
CA2312208C (en) 2011-01-25
DK1034298T3 (da) 2012-01-30
US20030166871A1 (en) 2003-09-04
IL136544A0 (en) 2001-06-14
IL136544A (en) 2007-07-24
BR9813365A (pt) 2004-06-15
JP4460155B2 (ja) 2010-05-12
US7087409B2 (en) 2006-08-08
AU1628099A (en) 1999-06-28
CY1112365T1 (el) 2015-12-09

Similar Documents

Publication Publication Date Title
ATE531812T1 (de) Humanisierung von nager-antikörpern
CA2469833A1 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
PT804237E (pt) Anticorpos humanizados contra a molecula de adesao leucocitaria vla-4
CY1121451T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα κατα του ctla-4
DK0979246T3 (da) Humane monoklonale antistoffer mod epidermal vækstfaktorreceptor
PT699237E (pt) Fvs de cadeia anti-egfr e anticorpos anti-egfr
NO20063224L (no) Anti-MPL-antistoff
KR950700414A (ko) 사람 인터루킨-4에 대한 사람화 모노클로날 항체의 클로닝 및 발현(Cloning and expression of humanized monoclonal antibodies against human interleukin-4)
DE50115580D1 (de) Verfahren zur Herstellung von Protein-Bibliotheken und zur Selektion von Proteinen daraus
EP2067788A3 (de) FAB-Fragmentbibliotheken und Verwendungsverfahren dafür
ATE509955T1 (de) Humanisierte kollagen-antikörper und damit verbundene verfahren
DE69828154D1 (de) Anti-alphavbeta3 humanizierte monoklonale antikörper
DE60238987D1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
ATE206621T1 (de) Il-8 antagonisten zur behandlung von asthma
EP1396539A4 (de) Humanantikörper gegen blutgerinnungsfaktor viii
ATE208403T1 (de) Antiidiotypische antikörper die eine immunantwort gegen den rezeptor für epidermalen wachstumsfaktor induzieren
ATE309371T1 (de) Protein mit dnase-aktivität
BR1100555B1 (pt) anticorpos monoclonais humanizados.
HUP9903273A3 (en) Anti-human mp52 monoclonal antibody